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ABSTRACT OF THE DISSERTATION  
Reliability and Validity of the Outcome Questionnaire  
in a Heterogeneous Cancer Population 
 by  Laura Testerman Doctor of Philosophy, Graduate Program in Psychology Loma Linda University, August 2012 Dr. Jason E. Owen, Chairperson  
The Institute of Medicine (IOM) and National Cancer Comprehensive Network 
(NCCN) now require integration of psychosocial care into the treatment of cancer 
patients to identify, monitor, and treat psychosocial distress.  Despite the widespread use 
of Patient Reported Outcomes (PRO) for these purposes, no gold standard PRO for 
assessing distress exists for psycho-oncology research and clinical practice. This study 
examined the reliability, validity, and preliminary treatment effects of the Outcome 
Questionnaire, a PRO never before been used or validated with heterogeneous cancer 
patients.  Adult cancer survivors were recruited nationwide to participate in an online 
support group (N=187) and randomly assigned to a treatment or wait-list condition in a 
longitudinal randomized controlled trial. The OQ Total Score demonstrated excellent 
reliability (α = 0.92).  However, the subscales varied in the quality of their reliability 
ratings.    Convergent validity was demonstrated, but divergent validity was not 
adequately shown.   Three new significant factors were identified through exploratory 
factor analysis.  For preliminary treatment effects in the online support group study, it 
was shown that those with a worse perceived health status F (1, 90) = 7.48, p = 0.008 and 
those who engaged more with the online support group improved over time F (1, 59) = 
 xv 
6.00, p = 0.018.  These findings suggest mixed support for the implementation of the OQ 
as a PRO in a chronic disease sample.  Generally, if the OQ is to be used as is within a 
cancer population, the Total Score may be interpreted as both reliable and valid and able 
to demonstrate treatment effects in a cancer population, but the subscale scores should 
not be interpreted.      
 
 
 1 
CHAPTER ONE 
INTRODUCTION   
The Institute of Medicine (IOM) and National Cancer Comprehensive Network 
(NCCN) now require integration of psychosocial care into the treatment of cancer 
patients to identify, monitor, and treat psychosocial distress ("Distress Management 
Clinical Practice Guidelines in Oncology," 2010).  Cancer patients experience 
significant levels of psychosocial distress related to numerous cancer and patient-related 
factors (Nicholas & Veach, 2000).  Treatment outcome evaluation of both currently 
utilized and newly developed psychosocial treatments is one way to ensure that a high 
quality standard of care is being provided.  Measuring the effectiveness and impact of an 
intervention or treatment via change in psychosocial distress from baseline to a follow-
up timepoint is an integral part of outcome measurement.  These measurements are 
normally assessed using patient reported outcome measurements (PROs).  Despite the 
widespread use of PROs for this purpose, no gold standard PRO for assessing distress 
exists for psycho-oncology research and clinical practice.  Many of the current PROs 
suffer from a variety of psychometric issues and it is often the case that measures 
employed in research settings are not widely used in clinical settings and vice versa 
(Luckett, et al., 2010).  A potential solution is to utilize the Outcome Questionnaire (OQ: 
Lambert, et al., 1996), a popular clinical outcome measure that has extensive use within 
general psychotherapy outcome research.  The OQ, despite its many potential benefits, 
has never before been used or validated within a chronic disease population such as with 
heterogeneous cancer patients.  The OQ may be advantageous in this population due to 
its content, sound psychometric properties, sensitivity to change, successful track record 
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of finding treatment effects, clinically meaningful interpretation, and practical 
administration. 
 
 
Cancer: Psychosocial Concerns 
 
Brief History of Psychosocial Care in Cancer Patients 
Cancer patient psychosocial care has not always been valued nor provided within 
the medical community.  Neither the Patient’s Bill of Rights nor the Joint Commission 
on Accreditation of Healthcare Organizations has mandated treatment for these 
concerns.  Not until 1997, when the NCCN formed an interdisciplinary panel, consisting 
of oncologists, psychiatrists, nurses, psychologists, social workers, clergy, and patient 
advocates, were formal clinical practice guidelines for cancer patient psychosocial care 
developed.  The benchmark publication in 1999 of these first guidelines for managing 
cancer patient distress included recommendations for identification, monitoring, and 
treatment of distress at all stages of cancer via screening for distress and psychosocial 
problems, creating and implementing a treatment plan for the identified problems, 
referring to appropriate psychosocial services as needed, and reevaluating the patient as 
necessary ("Distress Management Clinical Practice Guidelines in Oncology,” 2010).  
Effective treatment of cancer patient psychosocial distress is the ultimate goal of these 
standards.  These guidelines laid the groundwork for the IOM report on Cancer Care for 
the Whole Patient (Cancer care for the whole patient: Meeting psychosocial health 
needs, 2007) which supported the NCCN guidelines and established the necessity for 
psychosocial care as an integral standard for quality cancer patient care.  
 3 
NCCN guidelines recommend specific psychosocial screening measurement 
procedures for identification of distress but have not yet standardized outcome 
assessment of distress treatment.  Screening is a separate and distinct process from 
assessment of distress (Nicholas & Veach, 2000; Zabora, 1998).  It is considered a quick 
way for professionals to identify patients with psychosocial distress and to refer them for 
further assessment and treatment if scores meet a critical cut-point (Zabora, Smith-
Wilson, Fetting, & Enterline, 1990).  The NCCN recommends screening via a one-item, 
visual self-report questionnaire, the Distress Thermometer (DT), and an accompanying 
36-item problem checklist that the patient completes in the waiting room.  The problem 
checklist asks patients to endorse problems in five categories: practical, family, 
emotional, spiritual/religious, and physical.  The DT (Roth, et al., 1998), a one-item 
measure,  reads, “How distressed have you been during the past week on a scale of 0 to 
10,” and depicts a visual thermometer with a 0– 10 scale that ranges from “no distress” 
(0) to “extreme distress” (10).  Significant distress is indicated by scores four or higher.  
A score below four is not indicated for treatment or referral and at this level the primary 
oncology team typically self-manages distress via supportive care assistance.  Mild 
distress is considered to be in the range from 4-5, moderate distress ranges from 6-7, and 
8 or more is considered severe distress.  If a patient scores in any of these ranges, the 
NCCN recommends that the nurse review the accompanying problem checklist, identify 
core concern areas, and refer the patient to appropriate resources for treatment, including 
a mental health professional, social worker, or chaplaincy service.     
Assessment is a more in-depth evaluative process performed within the 
guidelines of the treating professionals’ clinical practice.  For psychological mental 
 4 
health professionals, the NCCN guidelines recommend a psychological evaluation that 
includes an assessment of the nature of the presenting problem of psychosocial distress, 
psychiatric history, decision-making ability, suicidality, and symptoms and behaviors 
surrounding pain, fatigue, sleep, sexuality, or other relevant physical ailments ("Distress 
Management Clinical Practice Guidelines in Oncology,” 2010).  Once assessed, the 
health professional begins treatment.   Currently, the quality of psychological treatment 
received is not monitored with any level of measurement.  The necessity for this type of 
evaluation is additionally supported by the NCCN, which identified the need for clinical 
health outcomes measurements to incorporate assessment of the psychosocial domain 
("Distress Management Clinical Practice Guidelines in Oncology,” 2010).  One option 
for monitoring the quality of treatment provided is via the use of a PRO measure, the 
OQ, which will be discussed in more depth later. 
 
Importance of Distress Treatment 
Early identification, assessment, and treatment of distress may benefit the 
patient, family, doctor, and the healthcare team.  Successful treatment of distress reduces 
healthcare costs and can improve quality of life (QOL) (Allison, et al., 1995; Deshields, 
Tibbs, Fan, & Taylor, 2006; Skarstein, Aass, Fossa, Skovlund, & Dahl, 2000).  
Increased distress may lead to reduction of some health behaviors needed for cancer 
prevention (Loscalzo & Brintzenhofeszoc, 1998; Pearlin & Schooler, 1978; Schou, 
Ekeberg, Ruland, Sandvik, & Karesen, 2004), delay in treatment seeking (Loscalzo & 
Brintzenhofeszoc, 1998; Pearlin & Schooler, 1978; Schou, et al., 2004), deterioration of 
doctor-patient communication ("Distress Management Clinical Practice Guidelines in 
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Oncology,” 2010), reduction of satisfaction with treatment (VonEssen, Larsson, Oberg, 
& Sjoden, 2002), increased treatment non-adherence (DiMatteo, Lepper, & Croghan, 
2000; Kennard, et al., 2004), increased number of anxiety-related doctor visitations and 
contacts ("Distress Management Clinical Practice Guidelines in Oncology,” 2010), and 
increased risk for morbidity and mortality of cancer (Antoni, et al., 2006; Giese-Davis & 
Spiegel, 2003; Spiegel & Giese-Davis, 2003).   Additionally, distress has been highly 
associated with decreased aspects of QOL, including physical, psychological, social, and 
spiritual well-being, for cancer patients and survivors (Deshields, et al., 2006; Skarstein, 
et al., 2000).   
The sincere risk associated with distress can be further elucidated by a 
metanalysis conducted by DiMatteo, Lepper, and Croghan (2000) which indicated that 
nonadherence was three times greater in depressed patients than those who were not 
depressed.  These results are even more startling when placed in the context of general 
nonadherence to drug treatment, for even non-depressed individuals frequently do not 
comply with treatment.  Findings have indicated that nearly half of cancer patients 
lacked compliance to an oral medication in the fourth year of treatment, indicating that 
over 25% may not gain the dosage necessary for a clinically positive outcome 
(Partridge, Wang, Winer, & Avorn, 2003).  Sadly, many more depressed individuals 
may fall into this negative outcome category, increasing risk of morbidity and mortality.  
Evidently, improving treatment of distress is vital.  An understanding of the prevalence, 
predictors, and nature of psychosocial distress cancer patients experience is helpful to 
understanding measurement of cancer patient distress that can ultimately identify 
efficacious and effective distress interventions.  
 6 
Psychosocial Distress 
Cancer patients not only have to endure physical symptoms related to their 
disease, but also high levels of psychosocial distress (Derogatis, Morrow, Fetting, & al., 
1983; Farber, Weinerman, & Kuypers, 1984; Stefanek, Derogatis, & Shaw, 1987).  
Psychosocial distress is common across the trajectory of the illness as well as during 
survivorship, frequently arising after diagnosis, at the onset or conclusion of treatment, 
periodically throughout treatment, at recurrence, and when shifting into palliative care, 
("Distress Management Clinical Practice Guidelines in Oncology,” 2010).  The NCCN 
guidelines define cancer patient psychosocial distress as: 
 
“a multifactorial unpleasant emotional experience of a psychological, social, 
and/or spiritual nature that may interfere with the ability to cope effectively with 
cancer, its physical symptoms, and its treatment.  Distress extends along a 
continuum, ranging from common normal feelings of vulnerability, sadness, and 
fears to problems that can become disabling, such as depression, anxiety, panic, 
social isolation, and existential and spiritual crisis.”   ("Distress Management 
Clinical Practice Guidelines in Oncology,” 2010) 
 
Thus, psychosocial distress encompasses issues of an emotional, psychological, 
spiritual, and social nature, including typical stress reactions as well as diagnosable 
mental disorders that may impede capability of dealing with cancer. The terminology 
“distress” was particularly selected by the NCCN in order to reduce stigma or 
embarrassment that may stem from use of the words “psychiatric” or “emotional.”  
Because clinicians opened up dialogue regarding patient pain by using a simple self-
report question, asking patients to assess their pain on a zero to ten scale, they felt that 
similarly it would be less offending to ask a patient to report “distress” on a zero to ten 
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scale.  Thus, the word “distress” was chosen because it can be defined and measured 
with self-report instruments.  
Thus, distress is both psychological and social in nature.  Because of the 
psychosocial nature of distress, many studies use the terminology “distress” and “quality 
of life” somewhat interchangeably, or create additional distinctions that do not exist 
between them, although neither approach is entirely accurate.  The definition for QOL is 
reportedly difficult to define (Bottomley, 2002) and has many overlapping 
characteristics with psychosocial distress.   QOL includes a larger overarching 
framework of well-being in physical, social, cognitive, spiritual, emotional, and role 
functioning areas (for example see Carlson & Bultz, 2003).   However, many studies of 
distress elect not to focus on any social issues of psychosocial distress, feeling that they 
are impinging on the realm of QOL, despite the definition of distress including social 
aspects (Carlson & Bultz, 2003).  Thus, many studies may not be appropriately gauging 
the totality of the experience of psychosocial distress.  Ganz and Goodwin (2005) make 
the argument that the best measurement of psychosocial interventions is via examining 
psychosocial distress.  They state that this may include measuring aspects of QOL (i.e. 
social aspects) without measuring the totality of QOL itself.   Thus, this study will 
include a focus on the nature, prevalence, predictors, and outcome measurement of 
psychosocial distress without focusing on the totality of QOL.   
Distress can be measured across a continuum, ranging from normal adjustment, 
to adjustment disorders, to subthreshhold mental disorders, to diagnosable mental 
disorders (America Psychiatric Association, 2000).  Typically at the time of diagnosis 
most individuals experience normal adjustment, or “expected distress,” symptoms.  
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These may consist of feelings of fear, loss, worry, anger, and uncertainty about the 
future and control over the world.  Also, troubles with sleep, lack of appetite, trouble 
focusing, and preoccupation with cancer, death, and treatment/side effects may arise.  
The patient’s oncology team often handles mild distress.  More pervasive and intense 
symptoms are indicative of moderate to severe levels of distress that are frequently 
referred to be treated by a mental health professional.  These symptoms include extreme 
worries, fears, sadness, despair, hopelessness, suicidality, family issues, and existential 
or spiritual problems ("Distress Management Clinical Practice Guidelines in Oncology,” 
2010).   
More severe problems and symptoms will fall along the continuum ranging from 
adjustment disorders to mental disorder diagnosis ("Distress Management Clinical 
Practice Guidelines in Oncology,” 2010).   To be diagnosed, adjustment disorders must 
occur within three months of the onset of a stressor and represent a maladaptive reaction 
or an inability to cope that has some marked effects on one’s ability to function at 
school, home, and/or work (America Psychiatric Association, 2000).  If mood and 
anxiety symptoms become more pervasive and severe or persist beyond six months, a 
more severe diagnosis may be indicated.      
Depressive disorders are more severe mood disorder diagnoses and also a 
common problem for cancer patients.  Many symptoms caused by the disease and/or 
treatment of cancer are identical to the symptoms necessary to meet criteria for 
diagnosis of depression, thus, making it more difficult to distinguish the mood disorder.  
Psychomotor retardation, appetite suppression, sleep disturbance, fatigue, concentration 
difficulties, and apathy are frequent symptoms in cancer and its treatment that also 
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imitate the mood disorder symptoms.  Distinctive symptoms for diagnosing a comorbid 
mood disorder include feelings of dysphoria and anhedonia, worthlessness, 
hopelessness, excessive or inappropriate guilt, and/or suicidal ideation (J.C. Holland & 
Alici, 2010).  Suicidal ideation in cancer patients occurs across all stages of the disease 
and is thought to act as a means for an individual to gain some sense of control over the 
illness (J.C. Holland & Gooen-Piels, 2003).  The risk of suicide is approximately two 
times that of the normal population (Breitbart, Lederberg, Rueda-Lara, & Alici, 2009; 
Chochinov, Wilson, Enns, & Lander, 1998), and an international population-based study 
indicated that the risk remained elevated even up to 25-years after a cancer diagnosis 
(Schairer, et al., 2006).  Thus, untreated distress can be deadly.  
In addition to depressive disorders, cancer patients commonly react with anxiety 
that is manifested physically as well as in thoughts and behaviors.  Holland and Alici 
(2010) reviewed the literature that discussed the most common types of anxiety 
disorders existing in cancer patients and indicated the following diagnoses: acute stress 
disorder, posttraumatic stress disorder (PTSD), generalized anxiety disorder (GAD), 
panic attacks or disorder, specific phobias, anxiety disorder due to a general medical 
condition, and substance-induced anxiety disorder.  
 
Prevalence of Distress 
Cancer patients experience significantly more psychosocial distress than other 
chronic disease populations or healthy adults (Kaiser, Hartoonian, & Owen, 2010).  
Studies on prevalence of distress indicate that one in three cancer patients will 
experience levels of significant distress (Derogatis, et al., 1983; Farber, et al., 1984; 
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Stefanek, et al., 1987), and depending on the study, a range of 5-47% of cancer patients 
report significant distress levels (Carlson, et al., 2004; Derogatis, et al., 1983; “Distress 
Management Clinical Practice Guidelines in Oncology," 2010; Kaiser, et al., 2010).  
Farber and colleagues (1984), utilizing the Symptom Check List-90 (SCL-90), detected 
34% of cancer patients with elevated distress.  Stefanek et al. (1987) identified 28% of 
cancer patients with distress after assessment with the Brief Symptom Inventory (BSI).   
Zabora and colleagues, also using the BSI, sampled larger cancer populations in 1997 
and 2001 (Zabora, et al., 1997; Zabora, BrintzenhofeSzoc, Curbow, Hooker, & 
Piantadosi, 2001).  In 1997, these researchers measured 386 patients from 12 American 
cancer centers and found levels of distress at 35%.  In 2001 they gathered information 
from 4496 participants with 35.1% reporting distress.  
The prevalence of psychiatric diagnoses in cancer patients has been reported to 
be as high as approximately 50% ("Distress Management Clinical Practice Guidelines in 
Oncology," 2010; J.C. Holland & Gooen-Piels, 2003; Massie, 2004).  Depending on the 
patient population and diagnostic criteria used, the majority of diagnoses include the 
following disorders and prevalence: adjustment disorders (estimates of 2/3rds of all 
diagnoses), depressive disorders (0-53%), and anxiety disorders (1-49%) (Derogatis, et 
al., 1983; Harter, et al., 2001; J.C. Holland & Gooen-Piels, 2003; Sellick & Crooks, 
1999; Van'T Spijker, Trijsburg, & Duivenvoordern, 1997; Zabora, et al., 2001).  
Adjustment disorders with anxiety and/or depressed mood represent the most common 
diagnoses for cancer patients (J.C. Holland & Alici, 2010).  In one of the earliest studies 
on psychiatric diagnosis in cancer patients, Derogatis and colleagues (1983) sampled 
patients from across 3 cancer programs and found that 47% were classified with a 
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Diagnostic and Statistical Manual of Mental Disorders (DSM) Axis I disorder based on 
a psychiatric interview and assessment with the SCL-90.  Approximately 1/3 of 
individuals in his sample met criteria for adjustment disorder with anxious or depressed 
mood, and 7% were severe enough to be classified with major depressive disorder 
(MDD).   
Inconsistent variations in distress across cancer patients are postulated to occur 
for a number of reasons.  Herschbach (2004), argues for a heterogeneous picture of 
distress results based on cancer type, indicating that a complex picture of factors within 
a cancer type may be more depictive than seeking general causes of distress across the 
totality of cancer diagnoses.  However, others argue that discrepancy in distress levels 
and predictors across studies may occur due to a lack of consistent nomenclature, 
measurement questionnaire, and different cut-off requirements for distress type and 
classification (Casarett & Inouye, 2001; Herschbach, et al., 2004; Luckett, et al., 2010; 
Massie, 2004).   
 
Risk Factors for Distress 
Correlates and predictors of distress, or risk factors for distress, may be 
categorized into cancer and patient-derived variables (J. C. Holland, 1998).  Nicholas 
and Veach (2000), after reviewing the literature, describe cancer-derived variables as 
those that refer to illness and treatment.  Patient-derived characteristics consist of 
demographic characteristics, past history, intrapersonal qualities, and interpersonal 
relationships. The authors support the position that a combination of history and 
demographic factors may influence the activation/perception of intrapersonal 
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characteristics and interpersonal relationships leading to distress.  A combination of the 
patient-derived and cancer-derived variables can lead to either normal adjustment or to 
experience of psychosocial distress.  The cancer and patient-derived risk factors for 
distress will be delineated.      
 
Cancer-Derived Risk Factors 
Holland and Alici (2010) summarized findings across the literature, and 
surmised that most cancer patients experience general fear and worry about disease 
reoccurrence, the future, current and/or potential symptoms from cancer and its 
treatment (i.e. pain, fatigue, death), phobias of health and hospital related treatment 
items (i.e. blood, needles), and anxiety induced by certain types of hormone-secreting 
cancers or substances used to treat the disease.  Research supporting cancer-derived 
variables as risk factors for increased distress is prevalent, but also mixed in findings.  
These risk factors include variables related to the disease, including cancer type, site, 
stage, and prognosis; treatment, both type and phase; comorbid illness and health 
factors; physical symptoms; and related disability processes that can result in 
psychosocial stressors (Nicholas & Veach, 2000; Turner, Wooding, & Neil, 1998). 
In 1999, Sellick and Crooks found that advanced stages of cancer, physical 
disability, and pain increased MDD.   Contrary to Sellick and Crook’s disease stage-
MDD relationship, Zabora (1997) found no correlation between stage of cancer and 
distress with the exception of the terminal phase, which indicated increased levels of 
distress.  Additionally, after sampling 4496 patients in 2001, Zabora et al. noted that 
distress rate varied by cancer type, with the following types reporting the most to least 
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distress: lung cancer (43.4)%, brain, Hodgkin’s disease, pancreas, lymphoma, liver, head 
and neck, breast, leukemia, melanoma, colon, prostate, and gynecological (29.6%).   
Similarly, Carlson et al. (2004) found that certain types of cancer patients reported the 
highest levels of distress, specifically lung, pancreatic, head and neck, Hodgkin’s 
disease, and brain cancer patients.  However, her findings differed from both Sellick and 
Crooks and Zabora et al.’s results, for her study indicated that active treatment patients 
were currently the most distressed.  Other findings demonstrated that fair or poor health 
status, experiencing pain, comorbid conditions (Kaiser, et al., 2010), duration of illness, 
and inpatient or outpatient setting (Herschbach, et al., 2004) are risk factors for distress.   
Disability processes related to the disease and treatment also are risk factors for 
psychosocial distress. The side effects of the treatment or illness may cause disruptions 
in patients’ daily activities and daily functioning, causing a shift for cancer patients’ 
roles in work, play, home, and love life (Dodd, et al., 2001; Lutgendorf, et al., 2000; 
Morasso, et al., 2001).  These shifts may lead to distress within the patient as well as the 
family as everyone experiences consequential shifts in their roles, structure, and needs at 
home and work (Hewitt, Greenfield, & Stovall, 2005).  Financial burden occurs as the 
patient’s employment status and healthcare costs may lead to depleted funds (Hewitt, et 
al., 2005).  In addition, intimacy and sexual functioning between patient and partner is 
frequently decreased (Aziz & Rowland, 2003).  With all of these substantial changes in 
functioning, survivors may struggle with indecision for how to move forward in their 
careers and/or intimate relationships (Hewitt, et al., 2005).   
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Patient-Derived Risk Factors 
Findings from patient-derived demographic variables as risk factors for distress 
are also prevalent.  Demographic risk factors commonly include age, gender, 
relationship status, and socioeconomic status (SES) (Nicholas & Veach, 2000).  
Research in this area has expanded over the past years, and a variety of studies indicate 
complicated findings for the significance of many of the following demographic 
predictors for increased distress in cancer patients: female gender, younger age, being 
unmarried, lower SES, lower levels of education, racial minority, higher number of 
children in the household, lower number of elders in the household, and lack of health 
insurance (Carlson, et al., 2004; Harter, et al., 2001; Herschbach, et al., 2004; Kaiser, et 
al., 2010; Zabora, et al., 2001).  
Patient-derived factors stemming from past history compose many other risk 
factors for distress.  Examples given of past history risk factors include prior mental 
disorders, substance abuse, and social history (Nicholas & Veach, 2000).  Turner, 
Wooding, and Neil (1998) reviewed the literature on breast cancer from 1986-1996 and 
deduced many risk factors for distress, including history of psychological problems.  
Prior psychiatric history is typically associated with a diagnosis of anxiety or depression 
at some point during the cancer disease trajectory. One study noted a previous history of 
depression in 31.5% of women that were diagnosed with early breast cancer and a 
comorbid depressive disorder (Kissane, et al., 1998).  The NCCN review provides a 
number of other problematic risk factors, including pre-morbid substance or alcohol 
abuse and previous physical or sexual abuse.   Additionally, pre-existing social 
relationship history may be influential. Turner and colleague’s (1998) review identified 
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recent loss of a spouse, marital problems, divorce, or widowhood, as increasing distress 
levels.   
Intrapersonal variables, such as personality and coping styles, and interpersonal 
patient variables, such as social support, are also identified as risk factors.  These factors 
individually or combined may influence the experience of distress.  High trait anxiety 
(Love, 2004), pessimism (Pinquart, Frohlich, & Silbereisen, 2007), an avoidant coping 
style, and/or unwillingness to disclose emotions (Turner, et al., 1998) are demonstrated 
to be influential in increasing distress.   Lack of social support, or perceived lack of 
support, is also a risk factor for psychosocial distress (Turner, et al., 1998).  Cancer 
patients may experience loneliness and isolation (Aziz & Rowland, 2003), and those 
living alone and who have communication barriers are also subject to higher degrees of 
distress ("Distress Management Clinical Practice Guidelines in Oncology," 2010).  Low 
perception of social support by those living alone and/or those exhibiting depressive 
coping behavior were associated with poorer adjustment (Sollner, et al., 1999).   
 
Patient Reported Outcomes 
Evidently, psychosocial distress is prevalent with numerous predictors related to 
the disease and the patient.  As discussed prior, although current NCCN guidelines 
require treatment for psychosocial distress, they do not monitor the outcome of 
treatment received.  Additionally, new and improved psychosocial treatments and 
interventions tested in epidemiological and clinical cancer studies need to be evaluated 
for their outcome effects.  Outcome evaluation of both currently utilized and newly 
developed psychosocial treatments is one way to ensure that a quality standard of care is 
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provided.  The necessity for this type of evaluation is additionally supported by the 
NCCN, which identified the need for clinical health outcomes measurements to 
incorporate assessment of the psychosocial domain ("Distress Management Clinical 
Practice Guidelines in Oncology," 2010).  Key to this type of research is measurement of 
outcome of psychosocial distress, most frequently assessed with PROs.   
Increasingly over the previous decades, PROs are serving as the core assessment 
for subjective concerns ("Distress Management Clinical Practice Guidelines in 
Oncology," 2010), such as anxiety, depression, distress, and QOL.  These measures are 
used to improve understanding of the outcome of treatments in supportive care and 
cancer treatment (Garcia, et al., 2007).  PROs are frequently being offered as paper-and-
pencil-based, self-report questionnaires or electronically as ePROs (Abernethy, et al., 
2010).  This self-report method has developed as an alternative to resource intensive 
clinical diagnostic interviews, for a wide variety of continuous data can be easily 
measured for those experiencing a wide range of severity of symptoms, from low to high 
severity (Luckett, et al., 2010).   Additionally, many PROs are now mandated for certain 
clinical trials as essential outcome assessments that contribute to clinical decision-
making.  For example, PROs could have contributed to clinical decision-making for a 
RCT comparing two leukemia treatments.  One treatment significantly improved QOL 
compared to another (Efficace, et al., 2008).  Thus, information gleaned from PROs may 
also provide a more complete picture of a patient and thus improve treatment (Efficace, 
Vignetti, & Mandelli, 2009).    
 Despite the increasing reliance on PROs in psycho-oncology research, no gold-
standard PRO currently exists to measure anxiety, depression, distress, and QOL across 
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cancer patients (Luckett, et al., 2010).  Flynn et al. (2006) summarized the concerns 
from qualitative interviews from 42 primary authors of clinical trials, including 11 
oncology researchers, published in top-tier journals.  They stated that the first problem is 
that clinical trials use different PROs to address identical constructs, making it difficult 
to compare findings across studies.  Second, many PROs suffer from problematic 
psychometrics.  Many have not been validated within cancer populations, are not 
sensitive to change, and suffer from floor or ceiling effects that minimize effect of a 
treatment intervention.  Third, many PROs are a burden for patients and administrators 
to complete or score.   
Additionally, many PROs measuring distress do not meet American 
Psychological Association (APA) standards for outcome measurement decided by the 
1994 APA-sponsored conference on developing outcome batteries (Horowitz, Lambert, 
& Strupp, 1994).  The group of 20 noted experts determined that the patient’s subjective 
distress, psychological symptoms, and impairment in social functioning (i.e., work, 
interpersonal relationships, etc.) were all necessary for appropriately measuring each 
patient’s unique problems.   Most PROS either assess psychological symptom distress or 
social distress, but not both processes (Jong, et al., 2007).  
Luckett and colleagues (2010) performed the first comprehensive oncology 
measurement outcome review.  These authors delineated guidelines for optimal PROs 
utilized within psycho-oncology research.  First, PROs need to have appropriate content 
and be shown to be suitable for a heterogeneous cancer population with people in 
varying types and stages of treatment.  Second, optimal PROs need to demonstrate 
sound psychometric properties including reliability and validity in English-speaking 
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cancer patients.  Most importantly, the measure needs to be sensitive to change.  Third, 
the track record of the measure is key.  The measure needs to have a history of finding 
treatment effects in randomized controlled trials (RCTs) of psychosocial interventions.  
Fourth, the measure needs to be interpretable.  Scores need to be clinically meaningful 
and comparison data needs to be available from both cancer and general populations.  
Finally, practical issues are key to a PRO being optimal.  A brief, low-cost measure 
available in many languages is ideal.  The PRO needs to be efficient in its length—
minimizing item number and maximizing constructs assessed, thus having minimal 
patient burden.  Next, the measure needs to have minimal administration and scoring 
burden. 
With these guidelines in mind, Luckett et al. (2010) evaluated publications 
between 1999 and May 2009 for numerous distress outcome questionnaires currently 
used to measure anxiety, depression, and distress.  These assessments have all been 
applied during psychosocial intervention RCTs within English-speaking, heterogeneous 
cancer populations.  They chose to exclude PROs that solely measured the psychological 
constructs of coping, adjustment, self-esteem, PTSD, and QOL.  Also excluded were 
measures that had one-third or greater of its items designated to measure somatic 
concerns or health preoccupation.  However, they included measurements that assessed 
a combination of anxiety, depression, and distress.  A total of 30 PROs were compared.  
The top three ranked scales in order of suggestion included the Hospital Anxiety and 
Depression Scale (HADS) (Zigmond & Snaith, 1983), the brief Profile of Mood States 
(POMS), the POMS-37 (Shachem, 1983), and the original POMS-65 (McNair & 
Heuchert, 2003) and the Center for Epidemiological Studies Depression Scale (CES-D) 
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(Radloff, 1977) tied for third.  However, none of these measures are commonly utilized 
within clinical practice settings.  Also, even after promoting these as the most optimal 
assessments, Luckett and colleagues still had reservations about these measurements.  
These measures and reservations based on the Luckett et al. findings will be outlined.        
The HADS (Zigmond & Snaith, 1983) is a 14-item measure rated on a four-point 
Likert scale asking patients to recall symptoms for the past seven days.  It takes 
approximately two to five minutes to complete. The cost is approximately $40 for the 
manual and 90 cents per patient form.   Subscale anxiety and depression scores are 
available, and the total score is seen as an “unofficial” score.  Although it ranked well in 
terms of its psychometric reliability and validity as well as its efficiency at measuring 
numerous constructs with only 14-items, there are problems involving the HADS overall 
score (HADS-T), content, and appropriate cut-offs.  Each problem within the HADS 
will be briefly discussed. 
Despite the HADS manual advising against utilizing the HADS total (HADS-T) 
score as an overall measure of distress (Snaith & Zigmond, 1994), many researchers 
continue to do so.  Content analysis of the HADS anxiety (HADS-A) and depression 
(HADS-D) scale indicate that only three items assess emotional experiences other than 
criteria necessary for GAD and MDD.  Therefore, positive findings for the HADS-T as 
an overall measure of distress are mixed, with some results indicating its superiority 
over the HADS-A and HADS-D in detecting clinically significant distress (Chaturvedi, 
1991; Katz, Kopek, Waldron, Devins, & Tomlinson, 2004; Le Fevre, Devereux, Smith, 
Lawrie, & Cornbleet, 1999; Lloyd-Williams, Friedman, & Rudd, 2001; Smith, et al., 
2006).  However, factor analyses demonstrated mixed results (Johnston, Pollard, & 
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Hennessey, 2000; Moorey, et al., 1991; Rodgers, Martin, Morse, Kendell, & Verill, 
2005; Smith, et al., 2002).  Additionally, RCTs were not utilized enough in the study to 
indicate the sensitivity to change of the HADS-T over time.  Luckett (2010) advised that 
further psychometric assessment of the HADS-T is needed.   
The content of the HADS also has several problems.  First, somatic content is 
completely omitted in hopes of reducing confounding disease and mood symptoms; 
however, this creates an overemphasis on symptoms of anhedonia.  Thus, the measure 
was not as valid within late-stage cancer as well as depressive disorders, for it may lack 
sensitivity to mild depression or adjustment disorder with depressed mood (Lloyd-
Williams, et al., 2001; Love, 2004).  Thus, the measure may not be the most sensitive to 
changes that occur post-intervention, and it may not demonstrate true treatment 
outcomes for some of these individuals.    
Lastly, the recommended cut-off scores by the HADS creators do not always 
perform well across studies, and optimal cut-off scores have differed (OHall, A-Hern, & 
Fallowfield, 1999).   Additionally, reporting of outcomes of the HADS sometimes takes 
different forms, such as means and standard deviations, and only sometimes with 
reference to cut-off scores.  Also, more research is necessary to determine an optimal 
cut-score for the HADS-T.  These cut-off score problems make clinically meaningful 
interpretation of the HADS very difficult.  It also becomes problematic to compare 
treatment effects across studies.  
The POMS-37 is a 37-item measure rated on a five-point Likert scale, asking 
participants to recall symptoms over the past seven days.  It takes approximately five 
minutes to complete and is free for non-commercial use.  It includes measures of 
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tension-anxiety, depression-dejection, anger-hostility, vigor, fatigue-inertia, and 
confusion-bewilderment.  A total mood disturbance score and individual subscale scores 
are available.  However, in the Luckett et al. (2010) study the total mood disturbance 
score was not counted as a distress measure because the score is calculated via addition 
of numerous subscales that included too many confounding somatic variables.  Luckett 
and colleagues noted the POMS-37 has a few significant problems including content and 
track record.  First, the measure was not created to screen for psychological disorders, 
but only to assess for mood.  Although it eases administrator cost and performs well for 
anxiety and mixed affective disorders, it does not offer a suitable index of general 
distress nor is it a good measure of depression for it also overemphasizes anhedonia.  
Second, it has only been utilized in one RCT of psychosocial interventions to assess for 
anxiety, depression, or distress since 1999 (Shachem, 1983).  This limits the track record 
for this instrument in finding significant psychosocial treatment effects.  
The original POMS-65 is a 65-item measure rated on a five-point Likert scale 
that asks participants to recall symptoms over the past seven days.  It takes 
approximately 10 minutes to complete.  The manual costs $27 dollars and each measure 
is $1.32.  It includes measures of tension-anxiety, depression-dejection, anger-hostility, 
vigor, fatigue-inertia, and confusion-bewilderment.  A total mood disturbance score and 
individual subscale scores are available.  Like the Poms-37 in the Luckett et al. (2010) 
study, the total mood disturbance score was not counted as a distress measure because 
the score is calculated via addition of numerous subscales that included too many 
confounding somatic variables.  The POMS-65 is also less appealing due to its cost and 
its length, and it is not perceived to be a very good measure of overall distress.  
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Finally, the CES-D (Radloff, 1977) is a 20-item measures rated on a five-point 
Likert scale based on the previous seven days.  It takes approximately five minutes to 
complete and is free for non-commercial use.  It provides a total score of depression.  
This measure is problematic for several reasons noted by Luckett et al. (2010).  First, its 
criterion validity has only been evaluated in two studies, and in one of these studies it 
was outperformed by the HADS-T, which has psychometric issues that have already 
been discussed.  Furthermore, the cognitive burden of the CES-D was ranked in the mid-
range due to its questions assessing symptom frequency rather than severity.  Finally, 
the CES-D is not a good measure for anxiety and distress, and it is a lengthy measure 
that examines only one construct.  
 
Solution: Alternative PRO, the Outcome Questionnaire 
Their conclusions demonstrate that an overall gold-standard measure for 
measuring anxiety, depression, and distress in cancer patients does not currently exist in 
the literature.  Many problems inherent in prior PROs may be resolved by incorporating 
the consistent use of a standardized psychological disturbance outcome measure in 
psycho-oncology cancer research.  One measure with laudable strength is the OQ 
(Lambert, et al., 1996).   The OQ is one of the top ten measures utilized in the United 
States for clinically measuring outcome of general psychosocial distress and functioning 
(Hatfield & Ogles, 2004).  As discussed prior, Luckett and colleagues (2010) made 
many recommendations for evaluating and appraising PROs as optimal.  Content, 
psychometric properties, track record, interpretability, and practical issues of the OQ are 
all key to classifying it as an optimal PRO.  These gold-standard PRO requirements will 
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be further discussed in terms of how the OQ already meets many of these guidelines 
and/or how the current study plans to fulfill any gaps in these standards.   
 
OQ Content 
Content of optimal PROs attempting to measure psychological distress should be 
suitable for a heterogeneous cancer population (Luckett, et al., 2010).  The OQ was 
specifically designed to measure key constructs and components of outcomes in global 
psychological distress and functioning.  Despite never being utilized within a cancer 
population, the OQ has been prominently used to measure general functioning and 
distress in patient-focused psychotherapy outcome research (for examples see: Harmon, 
et al., 2007; Lambert, Hansen, & Finch, 2001; Lambert, Harmon, Slade, Whipple, & 
Hawkins, 2005; Okiishi, et al., 2006; Slade, Lambert, Harmon, Smart, & Bailey, 2008; 
Whipple, et al., 2003).   A brief description of the OQ and a discussion of the rationale 
behind the measure’s item and domain selection may support its suitability for use as a 
measure of psychosocial distress within cancer patients.   
 
Description of the OQ 
The OQ (Lambert, et al., 1996) measures the global functioning and 
psychological disturbance of a client.  The assessment is a 45-question, five-point Likert 
scale self-report measure ranging from zero (never) to four (almost always), resulting in 
scores that range from 0 to 180.  Higher scores indicate a higher endorsement of 
disturbance.  Composed of three subscales, the OQ measures symptom distress (SD), 
interpersonal relationships (IR), and social role performance (SR).  Major symptoms of 
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psychiatric disorders, especially anxiety and depression, are assessed in the first 
subscale, Symptom Distress.  The second subscale, Interpersonal Relationships, 
measures satisfaction and problem areas of relationships.  Satisfaction and ability to 
function in primary roles such as in school, work, or home, are measured in the third 
subscale, Social Role.  The authors of the OQ argue that all three subscales contribute to 
a total score that captures global functioning and distress.   
 
Rationale Behind Item and Construct Selection 
All items and construct domains utilized in the OQ were selected rationally and 
empirically (Lambert, et al., 1996).  The content of the OQ has extensive clinical use 
and relevance, for the items and constructs were selected to examine three key domains: 
psychological symptom distress, interpersonal relationship problems, and social role 
functioning (Lambert, et al., 1996; Mueller, Lambert, & Burlingame, 1998; Umphress, 
Lambert, Smart, Barlow, & Clouse, 1997).  Mueller and colleagues (1998) noted how 
these three domains were designed to conceptually capture the definition of “mental 
disorder” given in the DSM (4th Edition): 
 
Each of the mental disorders is conceptualized as a clinically significant 
behavioral or psychological syndrome or pattern that occurs in an individual and 
that is associated with present distress (e.g., a painful symptom) or disability 
(i.e., impairment in one or more important areas of functioning).  (American 
Psychiatric Association, 1994, p. xxi) 
 
Thus, these domains of outcome meet the standards for outcome measurement decided 
by the 1994 APA-sponsored conference on developing outcome batteries: patient’s 
subjective distress, psychological symptoms, and impairment in social functioning (i.e., 
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work, interpersonal relationships, etc.) (Horowitz, et al., 1994).  These concerns were all 
considered necessary for appropriately measuring each patient’s unique problems.   
Most outcome measures pale in comparison by either assessing symptom distress or 
functioning but not both processes (Jong, et al., 2007).  
OQ researchers selected items to include in the Symptom Distress subscale based 
on reviewing survey data regarding psychological symptom and diagnosis prevalence in 
the U.S. population (Lambert, et al., 1996).   Analysis of the 1988 National Institute of 
Mental Health epidemiological questionnaire informed researchers that the most 
consistent symptoms and diagnoses included anxiety and depressive disorders closely 
followed by substance abuse problems (Regier, et al., 1988).  Thus, the OQ was heavily 
loaded with items that measure these symptoms.  Item selection was based on fit of 
items to current DSM criteria for these disorders, additional symptoms supported by the 
literature, and statistical analysis (Lambert, et al., 1996).  One limitation of the OQ is 
that a few items that were selected to best represent common symptoms of depression 
and anxiety may overlap with common physical problems due to cancer treatment side 
effects (e.g., fatigue, concentration).  However, without the inclusion of these items it 
may overestimate the symptoms of anhedonia and suffer from floor or ceiling effects of 
the score.   
Lambert and colleagues (1996) argue that the Interpersonal Relationships 
subscale domain was also founded upon research that indicates that, a) people consider 
relationship satisfaction key to personal happiness (Andrews & Withey, 1974; Beiser, 
1973 ; Blau, 1977; Diener, 1984; Veit & Ware, 1983) and, b) that interpersonal 
problems are the most prominently addressed issues in therapy (Horowitz, 1979; 
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Horowitz, Rosenberg, Baer, Ureno, & Villasenor, 1988).  Individual items were created 
based on marriage and family literature and research on patient-reported interpersonal 
problems for those in therapy (Horowitz, et al., 1991).  Items were thus selected in order 
to assess relationship conflict, loneliness, inadequacy, and withdrawal. 
Lastly, the social role performance domain was also included based on prior 
research.  Previous QOL research asserts that patient symptoms may influence their 
ability to perform at work, at home, and in relationships.  Satisfaction in personal and 
professional roles is correlated strongly with QOL (Beiser, 1973 ; Blau, 1977; Veit & 
Ware, 1983).  Thus, items were created to assess patients’ degree of distress within tasks 
associated with their play, work, and relationship roles.    
Overall, the content of the OQ is supported by the prior effort that went into 
developing the items and domains for assessing psychological distress and functioning.  
In order to determine if it is fully suitable for a heterogeneous cancer population, the 
psychometric properties will need to be closely examined within a sampling of these 
patients.       
 
OQ Psychometric Properties 
Gold-standard PROs need to be shown to be reliable and valid within the 
population that they purport to measure (Luckett, et al., 2010).  Prior psychometric 
studies have been conducted with the OQ in both normal and psychiatric patient 
populations.  Despite these prior studies, this measure has never before been validated in 
any cancer population or other chronic disease sample.  Examination of the previous 
reliability and validity studies may, a) support the psychometric properties of this 
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instrument and thus support its implementation within a cancer population, and b) give 
some indication for how the OQ may function in a cancer population.  These previous 
reliability and validity studies will be described, with a highlight of the findings noted.  
Based on these research findings, predictions will later be postulated regarding the 
reliability and validity of the OQ in a cancer population.   
 
Reliability 
Lambert and colleagues (1996) conducted the cornerstone study of the reliability 
of the OQ.  Undergraduate (N=157) and psychotherapy patient populations (N=289) 
were sampled to determine internal consistency of the OQ.  Excellent internal 
consistency was demonstrated for students and patients’ OQ total score (student/patient 
α = .93) as well as the Symptom Distress scale score (student α = .92; patient α = .91).  
The Interpersonal Relationships and Social Role scales, having greater variation in the 
functioning assessed in their measurements, demonstrated poorer reliability 
(Interpersonal Relationships: student/patient α = .74; Social Role: student α = .70; 
patient α = .71).  Undergraduate students (N=157) who received no therapeutic 
treatment were tested a second time at three weeks post-baseline assessment to examine 
test-retest reliability.  Pearson product-moment correlation coefficients indicated 
temporal-stability of the OQ over this time frame for the OQ total score (r=.84), 
Symptom Distress (r=.78), Interpersonal Relationships (r=.80), Social Role (r=.82). 
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Validity 
Concurrent validity of the OQ has been examined in two key studies, Lambert et 
al. (1996), which utilized an undergraduate population (N=238), and Umphress, 
Lambert, Smart, Barlow, and Clouse (1997), which sampled counseling center clients 
(n=53), community clinic patients (n=106), and an inpatient psychiatric population 
(n=24).  Both studies measured concurrent validity by computing Pearson product-
moment correlations between the OQ total and subscale scores and the criterion 
measures.  Both studies indicated similar validity patterns within their results.   
High levels of convergent validity were demonstrated across each study, for the 
OQ total and subscale scores had significant validity coefficients (p < 0.05) with all 
criterion measures.  The studies used the same criterion measures, although the Lambert 
et al. (1996) study utilized additional measures.  Within the Lambert et al. (1996) study, 
the General Severity Index (GSI) from the SCL-90-R,  Beck Depression Inventory 
(BDI), State-Trait Anxiety Inventory (STAI), Zung Self-Rating Depression Scale 
(ZSDS), Zung Self-Rating Anxiety Scale (ZSAS), Taylor Manifest Anxiety Scale 
(TMAS), Inventory of Interpersonal Problems (IIP), and Social Adjustment Scale (SAS) 
were utilized as the criterion measures. As hypothesized, the OQ total score and 
Symptom Distress subscale maintained moderate to high validity coefficients with all 
criterion measures (Total OQ: r = .60-.88, Symptom Distress: r = .50-.89), with 
depression (ZSDS, BDI), anxiety (TMAS, STAI, and ZSAS), and global distress (GSI) 
demonstrating the strongest relationships.  Despite subscale-criterion measure 
hypotheses, the Interpersonal Relationships and Social Role subscales did not correlate 
highest with their predicted respective measures, yet still correlated significantly with all 
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applicable measures (Interpersonal Relationships: r =.44-.67; Social Role: r =.41-.71).  
Umphress and colleagues (1997) criterion measures included only the GSI, IIP, and 
SAS-revised.  Again, although the OQ total and Symptom Distress subscale scores 
correlated as predicted with the respective criterion measures (Total OQ: r = .66-.88, 
Symptom Distress: r = .65-.92), the Interpersonal Relationships and Social Role 
subscales did not, despite their significant validity coefficient scores across measures 
(Interpersonal Relationships: r =.45-.69; Social Role: r =.53-.73).   
Lambert et al. (1996), Umphress et al. (1997), Vermeersch, Lambert, and 
Burlingame (2000) and Mueller, Lambert, and Burlingame (1998) each conducted 
research relevant to the construct validity of the OQ.  Multiple means of assessing 
construct validity were utilized in these studies, including examination of the following: 
the OQ’s sensitivity to change, a confirmatory factor analysis (CFA) of the subscales of 
the OQ, and the OQ’s ability to discriminate between psychiatric patient and non-patient 
populations. 
 OQ total and individual item score sensitivity to change were examined by 
Lambert et al. (1996) and Vermeersch, Lambert, and Burlingame (2000) respectively.  
Lambert and colleagues (1996) make the argument that the validity of a psychotherapy 
outcome measure like the OQ rests on its ability to demonstrate change in the desired 
direction following a therapeutic intervention.  Thus, scores of those not receiving 
psychotherapy would be expected to remain the same, however scores of those receiving 
psychotherapy would be expected to change in the direction of improvement.  Lambert 
et al. (1996) demonstrated support for total and subscale score sensitivity to change after 
examining data from 40 psychotherapy patients at baseline and after seven sessions of 
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outpatient psychotherapy treatment.  T-test comparison of pre and post-scores 
demonstrated significant improvement for patients across the total score and subscales. 
Expounding upon this idea, Vermeersch, Lambert, and Burlingame (2000) examined 
item-level sensitivity to change in a control group of undergraduate students (n=284) 
and an experimental group of individuals from four outpatient mental health groups 
(n=1176).  Results from hierarchical linear modeling indicated that the majority of items 
were sensitive to change in the optimal direction following treatment.  
 Despite favorable results for the OQ’s sensitivity to change, outcome of the CFA 
for the three subscales of the measure were not as preferable.  Three factor analysis 
models were assessed using a split-sample and cross-validating design (Mueller, et al., 
1998).  Model 1 tested a three-factor solution using the original three subscales of the 
OQ (Symptom Distress, Interpersonal Relationships, Social Role) as three oblique 
factors.  Model 2 analyzed a two-factor solution by examining two oblique factors—the 
original Symptom Distress and a new second factor that combined the Interpersonal 
Relationships and Social Role scales.  Lastly, Model 3 assessed a single-factor solution 
of all three original subscales.  Findings indicated that all models had a relatively poor 
fit.  However, chi-square analysis of the models indicated that Model 1, the three-factor 
solution, had a significantly better fit than the other models.  Other researchers have 
noted that the OQ may be examining one global distress factor, for the correlations 
between the subscales are significant (Umphress, et al., 1997).  Mueller and colleagues 
(1998) recommended that exploratory factor analysis should be performed in other 
patient populations.  Thus, this will be a focus for the current study. 
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 Discriminant validity findings regarding the ability of the OQ to discriminate 
patient and non-patient sample mean scores, examined by Lambert et al. (1996) and 
Umphress et al. (1997), supported the construct validity for this measure.  These studies 
compared a normal community sample with patient populations sampled from several 
types of mental health services centers.  In both studies, patient populations scored 
significantly higher on the OQ (x̅ = 67.6-99.9) than non-patient populations (x̅ = 42.3-
48.16), with the most severe patient populations (outpatient, inpatient) scoring the 
highest on the measure.  Umphress et al. (1997) further discriminated within the patient 
populations and noted a significant difference in pre-treatment total OQ scores for those 
diagnosed with a coded DSM disorder (x = 85.3) compared to those with a V-code score 
(x = 66.2).  Additionally, the Symptom Distress and Social Role subscales were 
significantly higher in those with a DSM disorder. Lambert and colleagues (1996) 
determined sensitivity (SE) and specificity (SP) by comparing classification accuracy for 
patient and nonpatient populations via the previously described 64-cutoff score.  The 
sensitivity index was .85, meaning that 85 out of 100 patients were correctly classified.  
The specificity index was .74, indicating that 74 out of 100 nonpatients were correctly 
classified.   
 
OQ Track Record 
In addition to content and psychometric properties suggesting suitability for a 
cancer population, optimal PROs should have a history of finding treatment effects in 
RCTs of psychosocial interventions.  Although never before examined in a cancer 
population, previous OQ research supports its ability to find treatment effects in RCTs.  
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Utilized within patient-focused outcome research, the OQ has repeatedly demonstrated 
significant treatment effects for this type of research.  The patient-focused research 
paradigm will be discussed as well as some of the significant findings demonstrated by 
the OQ.  Showing treatment effects of the OQ in a cancer population will be a focus for 
the current study.  
 
Theoretical Development of Patient-Focused Paradigm and  
Utilization of the Outcome Questionnaire 
Stemming partly from pressures of managed care third-party payers, consumers, 
and mental health workers to quantitatively demonstrate the benefit of psychological 
service, psychological outcome research originated.  The patient-focused research 
paradigm developed in response to limitations by various types of outcome research.  
This paradigm, dominated by the use of OQ-data, directly answers the question of 
whether the current client is being helped by the current treatment.  Clinicians receive 
current and consistent feedback on clients’ progress in therapy at every session (via the 
OQ scores) so that clinicians may alter treatments and prescribed therapeutic attendance 
as necessitated by the clients’ progress or lack thereof  (Howard, Moras, Brill, 
Martinovich, & Lutz, 1996).   
The patient-focused research paradigm was partially founded on two rationales 
or theories.  First, this paradigm declares that patient progress is often predictable, and 
positive or negative therapeutic outcome may be revealed in the first few sessions of 
therapy (Lambert & Bergin, 1994).  Thus, knowledge of patients’ level of distress and 
progress from session to session may increase therapists’ abilities to predict those who 
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may have a negative outcome.  Second, this research method was also in part developed 
using the rationale from the dose-response theory of therapy effectiveness.  The dose-
response theory indicates a linear relationship between the log of session numbers and 
the probability of patients’ positive progress.  Thus, the higher the dosage (number of 
therapy sessions), the better the response (patient progress) (Howard, Kopta, Krause, & 
Orlinsky, 1986).   Utilizing support from these theories, patient-focused researchers 
assert that feedback given to therapists on patient progress may increase/decrease the 
dose of therapy sessions or treatment, and thus better the outcome response (Lambert et 
al., 2001; Lambert et al., 2002; Whipple et al., 2003; Hawkins et al., 2004).  
The dose-response theory was also influential in developing a mathematical 
equation to assist in giving accurate patient-progress feedback.  Many patient-focused 
researchers are using an algorithm computed by Finch, Lambert, and Schaajli (2001) to 
identify clients at risk for having a negative outcome to therapy, or those clients who 
may drop out before receiving therapeutic benefits.  These algorithms use the clients’ 
intake level of distress (OQ-score) along with the change in OQ-score of client’s level of 
distress at the indicated session.  Next the client is classified on a range of functionality 
in either a “functional” or “dysfunctional” range based on Jacobson and Truax’s (1992) 
clinical significance definitions.  The feedback provided by the algorithm informs 
therapists if a client is making the expected amount of progress at a point in time to 
receive a clinically significant outcome.  Thus, patients may be labeled as on track (OT), 
if they are progressing normally, or not on track (NOT), if their progress is poor. 
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Significant Treatment Effects Found in RCTs via the OQ 
Many patient-focused research studies have examined the development and 
implementation of OQ-feedback systems that incorporate the use of the previously 
mentioned algorithm that assesses progress and change (e.g., Hawkins, Lambert, 
Vermeersch, Slade, & Tuttle, 2004; Lambert, Whipple, et al., 2001; Lambert, et al., 
2002 ; Whipple, et al., 2003).  These studies use an assigned experimental condition 
consisting of therapists that receive patient progress OQ-feedback (Fb), while the control 
condition did not receive patient OQ-feedback (NFb).  Each of these two conditions has 
clients that are represented by two status classifications based on the algorithm—NOT 
or OT.  The combination of the treatment levels and status conditions creates the 
following groups:  NOT-NFb (client is not progressing as expected and therapist is not 
receiving feedback), NOT-Fb (client is not making appropriate progress and therapist is 
receiving feedback), OT-NFb (client is making expected progress and therapist is not 
receiving feedback), OT-Fb (client is making expected progress and therapist is 
receiving feedback).  This is the basic crux for these RCTs, although many of the 
patient-focused paradigm studies add enhanced types of feedback (e.g.,Hawkins, et al., 
2004; Whipple, et al., 2003). 
The previous research conducted using the patient-focused paradigm indicates 
some important clinical trends as well as demonstrates support for the OQ’s ability to 
detect significant effect sizes.  First, consistent feedback of patient’s level of functioning 
and progress significantly improved overall patient functioning (measured by change in 
OQ-score from baseline to last session) and therapeutic outcome and attendance.  
Second, greater degrees of feedback and support contributed to more clinically 
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significant changes in overall patient functioning and therapeutic outcome (measured by 
change in OQ-score from baseline to last session). Thus, the OQ has consistently 
demonstrated significant treatment effects in patient-focused outcome research.   
 
OQ Interpretability 
A gold-standard PRO needs to be easily interpretable, having both clinically 
meaningful scores and comparison data available from both the desired population as 
well as the general population (Luckett, et al., 2010).  Prior research on the OQ has 
demonstrated clinically meaningful interpretation of the OQ scores as well as 
comparison data available for general and distressed populations.  
The OQ was designed to assess distress/functioning of individuals suffering from 
a broad array of V-Code, Axis-I, and Axis-II disorders, meaning that one can compare 
patients across vastly different diagnoses (Jong, et al., 2007).  Lambert et al. (1996) 
examined the OQ to determine the scores for clinically significant change and for the 
Reliable Change Index.  People with scores that increase or decrease by 14 points are 
seen as making “reliable change.”  The cut-off score from functional to dysfunctional is 
64 points, with higher scores being indicative of higher dysfunction.  To be considered 
“recovered,” one’s OQ score must decrease by at least 14 points and pass below the 64 
cut-off score.  “Improved” individuals have an OQ score that decreases by a minimum 
of 14 points but does not fall below the 64 cut-off score.  “No change” individuals’ score 
does not fluctuate by more than 14 points.  “Deteriorated” individuals must have an 
increase in score by 14 or more points.  Additionally, the OQ has been found to function 
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similarly across age and gender for both the total score as well as the subscales 
(Lambert, et al., 1996). 
 
OQ Practical Issues 
 In addition to each of the aforementioned qualities of a potential gold-standard 
PRO, practical issues of the measure such as ease of patient and administrator burden 
are key.  The OQ was designed as a low-cost measure with ease of administration and 
scoring (Lambert, et al., 1996).  The OQ can be given as a paper and pencil 
questionnaire or on a computer/PDA.  The creators of the OQ have developed a program 
so that the OQ can be easily scored electronically.  However, at 45-items, even the time 
to score it by hand is minimal for an administrator.  Thus, this measure is practical for 
use in outcome research.   
 
Current Study Aims and Hypotheses 
 The current study plans to further evaluate the properties of the OQ in order to 
fulfill appropriate standards recommended for a gold-standard PRO utilized in a cancer 
population.  
 
Aim One 
The first aim of the current study is to demonstrate the reliability of the OQ in a 
cancer population.  It is hypothesized that the OQ Total score and three subscales of the 
OQ will demonstrate reliability using Cronbach’s alpha.  
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Aim Two 
The second aim of the current study is to demonstrate the concurrent and 
construct validity of the OQ in a cancer population.   
It is hypothesized that concurrent validity will be demonstrated by showing 
convergent validity of the OQ total score and DT and the Functional Assessment of 
Cancer Treatment-General (FACT-G); the Symptom Distress subscale and the CES-D 
and Brief POMS; the Interpersonal Relationships subscale and the Social Support Scale 
and the FACT-G; and the Social Role subscale with the Social Constraint Scale and 
FACT-G. Additionally, the current study hypothesizes that concurrent validity will be 
supported by divergent validity of the OQ Total score and the Impact of Events Scale-
Revised (IES-R); the Symptom Distress subscale and Social Constraint Scale; the 
Interpersonal Relationships subscale and the CES-D; and the Social Role subscale with 
the Brief POMS.  It is hypothesized that construct validity of the three domains of the 
OQ will be demonstrated via an exploratory factor analysis.     
 
Aim Three 
The final purpose of the current study is to show preliminary treatment effects of 
using the OQ in a cancer population.  This will be examined in two ways.  First it is 
hypothesized that individuals who receive 12-weeks of treatment in an online support 
group (OSG) will show a significant decrease in their scores from baseline to post-test.  
However, it is postulated that individuals in a 12-week wait list for OSGs will show no 
difference in their scores from a baseline testing of their OQ distress and their start time 
in an OSG after a 12-week waiting interval.  Second, it is hypothesized that all 
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participants (treatment and control) will show a decrease in scores from the beginning of 
treatment to post-treatment.   
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CHAPTER TWO  
 
METHODS 
 
 
Participants 
 
 Participants were recruited primarily from the cancer registry at a cancer 
treatment facility, Loma Linda University Medical Center (LLUMC).  Additionally, 
efforts were made to recruit nationally using a variety of methods, including informative 
letters to health-care providers, flyers, newspaper advertisements, public service 
announcements, and Internet-based advertising.  Patients were considered eligible if they 
met the following criteria: adult (age 18 and over), cancer diagnosis, distress > 3 (based 
on DT’s 0-10 scale), English-language literate, and daily access to Internet. 
 
Design and Procedures 
LLUMC 
Cancer patients’ contact information was compiled based on the listings in the 
LLUMC cancer registry from July 2008 to July 2010.  Individuals on the registry are 
either diagnosed or treated for cancer at LLU during these years.   Recruitment via a 
cancer registry has been noted for raising some concerns as well as having obvious 
benefits for researchers and patients (Beskow, Sandler, & Weinberger, 2006).  While 
allowing access to a particular population, privacy regulation has been a noted issue for 
registry members.  However, the information gained via studies that utilize the registry 
recruitment methods has the potential to benefit registry members.  Rules, requirements, 
methods, and strategies for using a cancer registry have varied by registry and state.   
The most common approach allows researchers to notify physicians regarding their 
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study, receive contact information of participants via the cancer registry, and finally 
invite registry participants to participate in the study with an opt-out approach (Beskow, 
et al., 2006).   Other registries allow direct contact with registry members under the 
autonomy principle of human subjects protections (i.e., patients themselves are better 
judges of whether a study is of interest to them than would be their physician).  This 
approach was most similar to what was utilized in the current study as patients were 
directly contacted and invited to participate. 
Cancer registry members were mailed an informational letter inviting them to 
join an OSG for cancer patients and survivors.  Included was information regarding their 
ability to sign up or opt-out at anytime of future contact.  One week following the 
mailing of the letter, research assistants attempted to verbally recruit cancer registry 
patients by phone.  Participants who were reached within three to five phone calls were 
invited to participate in the study.  During the phone call, participants first were briefly 
informed about the nature of the study and screened based on the eligibility criteria.  
Those who passed screening were informed of the basic features of the website, how to 
make the most of their experience, and questionnaire and participation expectations.  
Patients who verbally consented were signed-up for the online support group, allowed to 
select a username and password, and automatically emailed an informational letter with 
a link to access the support group.  Lastly, they were instructed to read the informed 
consent page that would appear upon logging into the website and told that they could 
opt-out of further contact, and that consenting or declining would have no impact on 
their medical treatment or relationship with their physicians. 
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Nationwide Recruitment 
Cancer patients were recruited nationwide via a number of different methods.  
Physicians, social workers, and marriage and family therapists were mailed informative 
packets that included advertisement flyers that could be posted in offices.  Additionally, 
flyers, newspaper advertisements, public service announcements, and Internet-based 
advertising were used to recruit patients.  These advertisements directed patients to the 
website where they could learn more information and automatically enroll themselves in 
the OSG. 
 
All Participants 
Once patients logged into the confidential OSG, they are automatically directed 
through a series of screens.  First, the consent form appears and patients have the option 
to agree or decline.  Second, a baseline questionnaire appears and must be completed 
before a participant receives information regarding their randomization status.  After 
questionnaire completion, participants are informed whether they are randomized into 
the immediate treatment group or 12-week wait-list, control group.  The treatment group 
is asked to complete a questionnaire two weeks later, and at three and six months post-
baseline.  The control group is asked to complete a second survey at the end of their 12-
week wait, a questionnaire two weeks later, and then at three and six months post-
baseline.   Participants are reminded to complete questionnaires by email prompts, 
phone calls, and were mailed questionnaires with a stamped return envelope if a 
questionnaire had not been completed at four weeks post-due date.  Each participant was 
mailed a $10 reimbursement and thank you note for each questionnaire completed.   
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Measures 
OQ 
Psychological disturbance will be measured using the OQ-45 (Lambert, et al., 
2004).  The OQ-45 measures the global functioning of a client and is composed of three 
subscales that measure subjective discomfort (intrapsychic functioning), interpersonal 
relationships, and social role performance.   The OQ-45 has adequate internal 
consistency (α = .93) and test-retest reliability (r = .84) (Lambert, et al., 2004).  A 
number of studies have examined the validity of the OQ.  It has also been found to be 
sensitive to change over brief periods of time in treatment populations, while remaining 
the same in untreated people (Vermeersch, et al., 2000).  Umphress and colleagues 
(1997) concurrent validity criterion measures included the GSI, IIP, and SAS-revised.  
While the OQ total and Symptom Distress subscale scores correlated as predicted with 
the respective criterion measures (Total OQ: r = .66-.88, Symptom Distress: r = .65-.92), 
the Interpersonal Relationships and Social Role subscales did not have the strongest 
magnitude with their predicted measure, despite their significant validity coefficient 
scores across measures (Interpersonal Relationships: r =.45-.69; Social Role: r =.53-
.73).   
 
Distress Thermometer 
The DT (Roth, et al., 1998), a one-item measure, reads, “How distressed have 
you been during the past week on a scale of 0 to 10,” and depicts a visual thermometer 
with a 0–10 scale that ranges from “no distress” (0) to “extreme distress” (10).  
Significant distress is indicated by scores of four or higher.  Mild distress ranges from 
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four to five, moderate distress ranges from six to seven, and eight or more is considered 
severe distress.   A comprehensive review of the SE, SP, positive predictive value 
(PPV), and negative predictive value (NPV) supported its performance when examining 
distress but not anxiety or depression (Mitchell, 2007).  Specifically, for distress the 
study found an SE of 77.1%, SP of 66.1%, PPV of 55.6%, and NPV of 84.0%.  
However, for anxiety the SE was 77.3%, SP 56.6%, PPV of 55.2%, and an NPV of 
80.25%.  When measuring depression, the SE was 80.9%, SP of 60.2%, PPV of 32.8% 
and NPV of 92.9%.   
 
Fact-G 
The FACT-G scale (Cella, et al., 1993) is a 28-item general cancer QOL measure 
that results in a total score as well as subscales for physical, functional, social, and 
emotional well-being along with satisfaction with treatment relationship.  Test-retest 
reliability for the scales is the following: physical well-being (.88), functional well-being 
(.84), social well being (.82), emotional well-being (.82), satisfaction with physician 
relationship (.83), and total score (.92).  Validity was supported by hypothesized 
convergent and divergent validity scores with criterion measures.  Convergent validity 
was demonstrated by the total score correlation with the Functional Living Index-Cancer 
(r =.79), Brief Poms (r = -.65), and Taylor Mass Anxiety Scale (r = -.58).  However, 
correlation with social desirability, as measured by the brief M-CSDS, was low (r = .22). 
 
 
 
 44 
CES-D 
The CES-D (Radloff, 1977) utilizes 20 items on a four-point Likert scale to 
examine depressive symptoms in individuals.  Previous research has validated it for 
widespread use in cancer populations (Hann, Winter, & Jacobsen, 1999).  Validity 
studies have found good levels of relationship between the CES-D and other depression 
rating scales including the following: the Hamilton rating scale (r = .50s to .80s), the 
Raskin rating scale (r = .30s to .80s), the Lubin Depression Adjective Checklist (r = .40s 
to .50s) (Locke & Putnam, Unknown).  A previous lung cancer study has found it to 
have good reliability with this population (α = .79; Sanders, et al., 2009). 
 
Brief POMS 
The brief POMS is a 37-item shortened version of the original 65-item scale that 
attempts to identify mood states.  By utilizing a five-point-Likert-scale to endorse mood 
adjectives from “not at all” to “extremely,” participants are classifying moods across 
six-factors: tension-anxiety, depression-dejection, anger-hostility, and confusion-
bewilderment.  Total mood score is determined by subtracting vigor-activity from the 
sum of the other five scales.  Cronbach’s alpha ranges from .78 to .91 for each of the six 
subscales and for the total score.  Convergent and divergent validity were demonstrated 
by hypothesized correlations between the following: the POMS depression subscale and 
total score and the CES-D (both .63); the POMS fatigue and vigor subscales with the 
Self-Rated Karnofsky (-.40. to .39); the POMS fatigue and vigor subscales with the 
MOS SF-20 Physical Functioning (both -.42); the POMS-vigor scale and the Bradburn 
Positive Affect Scales (.53); the POMS total score and the Bradburn Negative Affect 
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Scales (.60); and low correlations between the POMS anger, confusion, depression, and 
tension subscales with the MOS SF-20 Physical Functioning and the Self-Rated 
Karnofsky  (-.08 to -.20).  Additionally a CFA supported the six-factor structure of the 
POMS (Baker, Denniston, Zabora, Polland, & Dudley, 2002). 
 
Social Support Scale 
The six-item social support scale is a combination of two, 3-item subscales 
drawn from the 29-item Yale Social Support Index.  The Positive Emotional Support 
(PES) subscale and Aversive Emotional Support (AES) scale assess the quantity and 
quality of social support and interaction on a four-point Likert scale.   Construction of 
items on these subscales was standardized per item in order to allow items to be 
aggregated onto the appropriate scale.  A prior study conducted by Butler, Koopman, 
Classen, and Spiegal (1999) has utilized these subscales and found Cronbach alpha at 
.71 for the PES, and .68 for the AES.   Although the validity coefficients could not be 
found, these subscales have also been utilized in Koopman et al. (1998).  
 
Social Constraint Scale 
 The Social Constraint Scale (S.J. Lepore & Ituarte, 1999) is a 15-item measure that 
assesses social constraints, specifically with “friends and family” in this version, on 
disclosure of distressing feelings and thoughts related to cancer.  On a four-point Likert 
scale participants rate a variety of social constraint experiences in the prior four weeks.  
The coefficient alpha has ranged from .89 to .92.  This measure has been found to have 
good convergent validity with the Mental Health scale from the MOS-SF36, as well as 
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the Negative Affect scale from the PANAS.   Additionally, divergent validity is 
supported, for the scale was generally not significantly associated with the amount of 
social support received as measured by the UCLA social support scale (S.J.  Lepore, 
2001). 
 
IES-R 
The IES-R (Weiss & Marmar, 1996) assessed the post-traumatic emotional 
reactions of patients dealing with their cancer diagnosis and symptoms.  The measure 
includes 22 items, three subscales (intrusiveness, avoidance, and hyperarousal scale), 
and a five-point, Likert-scale format.  Good reliability was found in a previous lung 
cancer research study (α = .89; Sanders, et al., 2009).  The IES-R has been utilized in a 
variety of cancer-related studies (Lindberg & Wellisch, 2004; Mehnert & Koch, 2007; 
Sanders, et al., 2009) and has been found to be highly valid.  The PTSD Checklist and 
IES-R correlate at high levels (r = .84) demonstrating convergent validity (Creamer, 
Bell, & Failla, 2003). 
 
Data Analysis 
Aim One 
The first aim of the current study was to demonstrate the reliability of the OQ in 
a cancer population.  This was examined by a Cronbach’s alpha analysis for the OQ 
Total score and 3 subscale totals of the OQ.  Cronbach’s alpha was ranked according to 
guidelines supplied by George and Mallery (2003): > .9 excellent, > .8 good,  > .7 
acceptable, > .6 questionable, > .5 poor, and < .5 unacceptable (p. 231). 
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Aim Two 
The second aim of the current study was to demonstrate the concurrent and 
construct validity of the OQ in a cancer population (see Figure 1).  
 
 
 
Figure 1. Hypothesized absolute values of convergent and divergent validity for the OQ 
Total Score, Symptom Distress, Interpersonal Relationships, and Social Role scales. 
DT= Distress Thermometer; FACT-G= Functional Assessment of Cancer Therapy – 
General; CES-D= Center for Epidemiologic Studies Depression Scale; POMS= Profile 
of Mood States; SSS= Social Support Scale; SCS= Social Constraint Scale; IES-R= 
Impact of Event Scale-Revised. 
 
 
 
Concurrent validity was examined via significant correlations (p < .05) between the OQ 
total score and DT and FACT-G; the Symptom Distress subscale and the CES-D and 
Brief POMS; the Interpersonal Relationships subscale and the Social Support Scale and 
the FACT-G; and the Social Role subscale with the Social Constraint Scale and FACT-
G.  Divergent validity will be supported by insignificant correlations (p > .05) between 
the OQ Total score and the Impact of Events Scale; the Symptom Distress subscale and 
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Social Constraint Scale; the Interpersonal Relationships subscale and the CES-D; and 
the Social Role subscale with the Brief POMS.  Power was calculated via G*Power for 
bivariate normal correlations with ∝= .05, two-tailed test, power = .80, correlation p 
(Ho) =0.00.  The sample size required 84 participants in order to be adequately powered 
for r >  .30.   
Further construct validity of the three domains of the OQ was examined by 
conducting an exploratory factor analysis.  Parallel analysis determined the number of 
factors extracted as five (Hayton, Allen, & Scarpello, 2004).  When the items were re-
factored, the principle axes method was used, with five factors extracted, Varimax 
rotation, and loadings sorted by size while suppressing loadings that were less than .15.  
A significant factor must have at least three items that load on or above .30, or it has a 
minimum of two variables that load at .50 or greater.  If any of these salient items cross-
load closer than .13 with another item than they are no longer considered salient.  If 
there are any non-significant factors, the factor number will be reduced by one and the 
process will be repeated until there are no trivial factors.  If Cronbach’s Alpha is smaller 
than .60 for any factor’s set of salient items, the number of factors should will be 
decreased by one and then re-factored. 
 
Aim Three 
The final purpose of the current study was to show preliminary treatment effects 
of using the OQ in a cancer population.  This aim was evaluated in two ways.  First, all 
participants were examined for treatment effects by conducting a repeated measures, 
within factors analysis of covariance (ANCOVA) examining the appropriate measures 
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from the beginning and completion of treatment (i.e. OSG = Time 1 to Time 2; Wait = 
Time 2 to Time 3).  Significant measure differences in the direction of improvement 
after an OSG intervention were indicated by p < .05.   Second, an interaction of 
treatment group by time was examined by conducting a repeated measures, between-
within factors ANCOVA examining differences between the treatment group (Time 1 to 
Time 2) and control group (Time 1 to Time 2).  It was expected that there would be a 
significant interaction, indicated by p < .05.  Also, the treatment group should have 
significantly lower Time 2 scores than the control group.   Power was identical for both 
ANCOVAS, and was examined for repeated measures, within-between interaction as 
well as a within-interaction.  Using G*Power, the following were used for the a-priori 
power analysis: F test family, effect size (f)2 = .25, alpha error probability = .05, power 
= .80, with two groups, two times of measurement, and a correlation among repeated 
measures of .50.  In order to meet critical F = 4.15, the sample size would need to be 34.  
Our current sample size exceeds this requirement.     
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CHAPTER THREE 
RESULTS 
 
Characteristics of Participants 
 
Characteristics of participants are presented in Table 1.  A majority of 
participants identified themselves as White (86.3%), female (69.8%), and married 
(68.1%).  Participants averaged a mean age of 52.7 years with 15.4 years of education, 
and had a 5% trimmed median household income of $62,500.  The highest number of 
participants reported not knowing their cancer stage (25.3%), followed by Stage II 
(20.9%); suffered from breast (28%) or prostate (17%) cancer; and received surgery as 
treatment (67%).  Moderate to significant distress (DT: x̅ =6; OQ: x̅ = 69) was average. 
 
Table 1 
Characteristics of Participants  
Participant Characteristics (N = 182) x̅  (sd) % 
   
Age (years) 52.7 (11.8)  
Gender (% Female)  69.8 
Education (In Years) 15.4 (2.5)  
Ethnicity    
White   86.3 
Other   4.9 
Latino  4.4 
African American  3.3 
Asian  1.1 
Income (Median) $62,500 ($57,313)  
Marital Status   
     Married  68.1 
     Single  14.8 
     Divorced  13.2 
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Table 1. Continued. 
     Widowed  3.8 
Cancer Stage   
     I  16.5 
    II  20.9 
    III  18.1 
    IV  14.3 
    Insitu  4.9 
    Unsure  25.3 
Cancer Type   
    Breast  28.6 
    Prostate  17.2 
    Thyroid  7 
    Female Reproductive (ovarian)  6.6 
    Melanoma  2.6 
    Blood/Leukemia/Lymphoma  5 
    Bladder/Kidney  1.5 
    Colon/Rectum  3.0 
    Lung  2.5 
    Multiple  3.0 
    Other  23 
Cancer Treatment   
     Bio (?) 
 
 3.3 
    Chemotherapy  42.9 
     Hormone Therapy  17 
     Immunotherapy  4.4 
     Surgery  67 
     Xrt   47.8 
Outcome Questionnaire (0-180, >63 distress)   
    Total Time 1 69.3 (21.8)  
    Symptom Distress 41.4 (14.3)  
    Interpersonal Relationships 16.3 (6.6)  
    Social/Role Functioning 11.6 (4.3)  
Distress (1-10; > 4 = distress) 6 (2.2)  
FACT-G Total (0-108; lower = lower QOL) 64.8 (18.4)  
CESD Total (>16 cutoff for depression) 22.5 (11.9)  
POMS Total  (0-124; higher = higher 
distress) 
37.7 (28.8)  
SSS Total (6-24; higher = higher support) 17.9 (3.2)  
SCS Total (15-60; higher = more constraint) 29.5 (11.5)  
IES-R Total (0-88; higher = more neg) 26.2 (15.8)  
Note.  XRT= External Beam Radiation Therapy; FACT-G= Functional Assessment 
of Cancer Therapy – General; CES-D = Center for Epidemiologic Studies 
Depression Scale; POMS= Profile of Mood States; SS= Social Support Scale; SCS= 
Social Constraint Scale; IES-R = Impact of Event Scale-Revised. 
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Aim One: Reliability of the OQ 
 The OQ Total Score demonstrated excellent reliability (α = .92).  However, the 
subscales varied in the quality of their reliability ratings.  Whereas the Symptom 
Distress scale exemplified excellent reliability (α = .91), the Interpersonal Relationships 
only showed good/acceptable reliability (α = .80), and the Social Role displayed poor 
reliability (α = .59). 
 
Aim Two: Concurrent and Construct Validity of the OQ 
Concurrent Validity 
Validity coefficients for the OQ Total Score, Symptom Distress, Interpersonal 
Relationships, and Social Role subscales with the DT, Fact-G, CES-D, Brief POMS, 
SSS, SCS, and IES-R, may be viewed in Table 2.  All criterion measures were 
significantly correlated with the OQ Total, Symptom Distress, Interpersonal 
Relationships, and Social Role scores.  The OQ Total (r = .836) and Symptom Distress 
(r = .836) subscale scores were most highly associated with depression (CES-D), 
whereas Interpersonal Relationships correlated most strongly with social support (SSS: r 
= -.643) and the Social Role with negative moods (Brief POMS: r = .525).  
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Table 2 
 
Intercorrelations for OQ Scores and Patient Reported Outcome Measures 
V 1 2 3 4 5 6 7 8 9 10 11 
1 1           
2 .947 1          
3 .792 .605 1         
4 .690 .538 .457 1        
5 .592 .581 .481 .348 1       
6 -.795 -.778 -.639 -.464 -.568 1      
7 .836 .836 .633 .510 .611 -.835 1     
8 .831 .831 .606 .525 .603 -.821 .889 1    
9 -.586 -.467 -.643 -.452 -.289 .554 -.466 -.439 1   
10 .637 .632 .508 .366 .338 -.637 .630 .594 -.578 1  
11 .664 .700 .414 .419 .524 -.657 .714 .696 -.312 .572 1 
 
Note. V= Variable; 1= OQ Total; 2=OQ SD; 3=OQ IR; 4=OQ SR; 5=DT; 6=Fact-G; 
7=CES-D; 8=Brief POMS; 9=SSS; 10=SCS; 11=IES-R.  All correlations = p < .001.  
 
 
 
A graphic representation of the outcome of the convergent and divergent validity 
of particular hypothesized measures may be seen in Figure 2.  Convergent validity was 
demonstrated across all measures for the OQ Total, Symptom Distress, Interpersonal 
Relationships, and Social Role scores; however, divergent validity was not 
demonstrated.   
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Figure 2. Absolute values of validity coefficients for the OQ Total Score, Symptom 
Distress, Interpersonal Relationships, and Social Role scales. DT=Distress 
Thermometer; FACT-G= Functional Assessment of Cancer Therapy – General; CES-
D = Center for Epidemiologic Studies Depression Scale; POMS= Profile of Mood 
States; SSS= Social Support Scale; SCS= Social Constraint Scale; IES-R = Impact of 
Event Scale-Revised. 
 
 
Construct Validity 
Parallel analysis determined the number of factors extracted as five (Hayton, 
Allen, & Scarpello, 2004).  When the items were re-factored, the principle axes method 
was used, with five factors extracted, Varimax rotation, and loadings sorted by size 
while suppressing loadings that were less than .15.  Varimax rotation was selected 
because it forces items to be uncorrelated and thus most clearly defines the structure of a 
factor conceptually.  The loadings were ordered by size for ease of viewing, and 
loadings under .15 were suppressed because they were the most insignificant.  
Significant factors were required to have at least three items that load on or above .30 or 
0 0.1 
0.2 0.3 
0.4 0.5 
0.6 0.7 
0.8 0.9 
OQ Total Score  Symptom Distress  Interpersonal Relationship  Social Role Functioning 
A
b
so
lu
te
 V
al
u
e 
of
 V
al
id
it
y 
Co
ef
:i
ci
en
ts
 
DT Fact‐G CES‐D Brief POMS SSS SCS IES‐R 
 55 
have a minimum of two variables that load at .50 or greater.  If any salient items cross-
loaded closer than .13 with another item than they were no longer considered salient.  
For factors that did not meet the minimal significance criteria, the factor number was 
reduced by one and the process was repeated until there were no trivial factors.  If 
Cronbach’s Alpha was  smaller than .60 for any factor’s set of salient items, the number 
of factors was decreased by one and then re-factored.  Through this process five factors 
were reduced to three significant factors (see Table 3).  The three factors differed from 
the original three factor subscales and were renamed the following: Factor 1, Sense of 
Well-being; Factor 2, Symptom Distress; Factor 3, Externalizing Behaviors. 
 
Table 3 
Means, Standard Deviations, Rotated Factor Loadings, and Communalities for OQ 
Items  
   Factor Loadings 
Item (Prior Factor Subscale) x̅ SD h2 1 2 3 
31 (SD): I am satisfied with my life 1.85 1.053 .770 .782 .252   
 13 (SD): I am a happy person 1.44 .902 .682 .724     
20 (IR): I feel loved and wanted 1.47 1.041 .668 .719     
43 (IR): I am satisfied with my 
relationships with others 
1.45 .951 .644 .696   .162 
37 (IR): I feel my love relationships 
are full and complete 
1.91 1.359 .629 .670     
24 (SD): I like myself 1.48 .975 .676 .651 .187   
21 (SR): I enjoy my spare time 1.63 1.044 .594 .647     
12 (SR): I find my work/school 
satisfying 
1.78 1.203 .636 .563 .162 -.186 
15 (SD): I feel worthless 1.41 1.033 .639 .509 .440   
1 (IR): I get along well with others .63 .824 .523 .505   .203 
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3. 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7 (IR): I feel unhappy in my 
marriage/significant relationship 
1.56 1.257 .544 .447 .218   
30 (IR): I have trouble getting along 
with friends and close acquaintances 
1.00 .789 .531 .421 .247 .257 
8 (SD): I have thoughts of ending my 
life 
.57 .864 .450 .397 .190   
17 (IR): I have an unfulfilling sex life 2.43 1.338 .435 .348     
19 (IR): I have frequent arguments 1.31 .903 .458 .313 .226 .210 
42 (SD): I feel blue 1.98 .986 .707 .345 .698   
9 (SD): I feel weak 2.04 1.132 .707 .192 .655 -.158 
36 (SD): I feel nervous 1.78 1.082 .566 .185 .603 .222 
10 (SD): I feel fearful 1.90 1.028 .603   .599   
22 (SD): I have difficulty 
concentrating 
2.27 1.047 .630 .261 .597 .196 
23 (SD): I feel hopeless about the 
future 
1.86 1.096 .676 .479 .566   
41 (SD): I have trouble falling asleep 
or staying asleep 
2.30 1.317 .478   .562   
2 (SD): I tire quickly 2.50 .911 .664   .554 -.263 
33 (SD):  I feel that something bad is 
going to happen 
1.73 1.089 .635 .252 .548   
6 (SD): I feel irritated 2.23 .857 .635 .351 .535 .293 
34 (SD): I have sore muscles 2.15 1.093 .519   .525   
40 (SD): I feel something is wrong 
with my mind 
1.47 1.133 .589 .367 .501 .152 
5 (SD): I blame myself for things 2.07 1.031 .588 .356 .494   
29 (SD): My heart pounds too much 1.24 1.067 .407   .491 .153 
3 (SD): I feel no interest in things 1.90 .943 .615 .431 .490   
18 (IR): I feel lonely 2.06 1.079 .630 .420 .462   
16 (IR): I am concerned about family 
troubles 
2.30 1.111 .435 .244 .437   
27 (SD): I have an upset stomach 1.54 1.103 .424   .420   
25 (SD): Distrubing thoughts come 
into my mind that I can’t get rid of 
1.59 1.085 .539 .220 .401   
45 (SD): I have headaches 1.40 1.094 .437   .339   
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28 (SR): I am not working/studying as 
well as I used to 
2.03 1.140 .530   .310 .164 
35 (SD): I feel afraid of open spaces, 
or driving, or being on buses, 
subways, and so forth 
.50 .860 .363   .261 .249 
11 (SD): After heavy drinking, I need 
a drink the next morning to get going  
.15 .457 .614     .653 
32 (SR): I have trouble at work/school 
because of drinking or drug use 
.08 .324 .622     .637 
26 (IR): I feel annoyed by people who 
criticize my drinking (or drug use) 
.20 .621 .550     .549 
39 (SR): I have too may disagreements 
at work/school 
.62 .740 .541 .242   .525 
44 (SR): I feel angry enough at 
work/school to do something I may 
regret 
.36 .715 .524 .280   .516 
4 (SR): I feel stressed at work/school 2.05 1.112 .618   .378 .435 
38 (SR): I feel that I am not doing well 
at work/school 
1.38 1.086 .586 .157 .201 .389 
14 (SR): I work/study too much 1.69 1.180 .428 -.211   .315 
 
Note.  Boldface indicates highest factor loadings. Factor 1 = Sense of Well-Being; 
Factor 2 = Symptom Distress; Factor 3 = Externalizing Behaviors; OQ = Outcome 
Questionnaire; h2= Communality. 
 
 
 
Aim Three: Preliminary Treatment Effects 
 Finally, a series of repeated measure ANCOVAs were conducted in order to 
examine whether the OQ can indicate preliminary treatment effects of an OSG in a 
cancer population.  This aim was evaluated in two ways.  First, to discern if the OQ can 
detect a difference over time, all participants, regardless of level of engagement in the 
support groups, were evaluated for improvement from baseline to post-treatment while 
controlling for health status.  Secondly, analyses were conducted to determine if the OQ 
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could distinguish the difference between a treatment and control group when controlling 
for health status.  
 
Improvement Post-Treatment 
First, all participants, regardless of treatment condition or level of engagement in 
OSG, were examined for treatment effects over time by conducting a repeated measures 
ANCOVA.  The repeated measures ANCOVA examined the participant scores from 
baseline to post-treatment with perceived physical well-being, as measured by the 
FACT-G physical well-being subscale, used as a covariate.  Table 4 can be consulted for 
baseline and post-treatment OQ means and standard deviations for all participants.  
Greenhouse-Geisser was used as a significance level due to Mauchly’s Test of 
Sphericity not being valid.  As seen in Table 5 and Figure 3, there was a significant 
decrease in distress as measured by the OQ from Time 1 to Time 2, F (1, 60) = 5.78, p = 
.019.  
 
Table 4 
Means and Standard Deviations for Two Treatment (Tx) Groups and Repeated Testing 
Times of the OQ 
 
Pre-Tx 
Baseline: 
OQ Total Time 1 
Post-tx: 
OQ Total Time 2 
Tx Group (n) x̅ SD x̅ SD x̅ SD 
All Participants (63) NA NA 66.92 25.56 59.89 23.43 
Experimental (46) NA NA 72.09 24.30 62.61 23.52 
Control (Pre-tx and 
T1 = 48; T2 = 17) 
62.63 19.10 52.94 24.23 52.53 22.21 
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Table 5 
Effect of Time on OQ Scores While Controlling for FACT-G Physical Well-Being (PWB) 
Source df Type III SS MS F 
Within Subjects 
Time 1 573.69 573.69 5.78* 
Time x FACT-G 
PWB 
1 189.90 189.90 1.91 
Error 61 6059.07 99.33  
 Between Subjects  
FACT-G PWB 1 114226.94 114226.94 153.00*** 
Error 61 45542.35 746.60  
 
Note. *p < .05, ** p < .01, ***p < .001. Time= Baseline (1) and Post (2) Treatment.  
 
 
 
 
 
Figure 3. All participants Total Mean OQ scores from Time 1 to Time 2 while 
controlling for Fact-G physical well-being (x̅  = 19.12).   
 
 
 
56 58 
60 62 
64 66 
68 
Time 1  Time 2 
Total OQ Score 
Total OQ Score 
 60 
Interaction of Treatment Group by Time 
 Next, the data was analyzed in order to discern if the OQ can detect not only a 
difference over time, but also to distinguish significance of the experimental group that 
received treatment when compared to a control group over time.  An interaction of 
treatment group by time was examined by conducting a repeated measures, between-
within factors ANCOVA examining differences between the treatment group (baseline 
to post-treatment) and control group (pre-treatment to baseline) while covarying for self-
perceived level of physical well-being as measured by the FACT-G physical well-being 
subscale. 
 Some assumptions of a repeated measure ANCOVA were examined before 
results were interpreted.  First, homogeneity of variance across levels of treatment 
groups was assessed using Box’s M Test.  Since Box’s M was significant (p = .002), 
indicating that the variance across levels of treatment may not be the same, Levene’s 
tests were examined for significant inequality across the dependent variables.  Since 
neither Levene’s test was significant for either univariate analysis for OQ Time 1 (p = 
.59) or 2 (p = .40), it was decided that equality could be assumed and that likely 
hypersentivity of Box’s M lead to its flagged significance. Thus, the model results were 
still examined. Greenhouse-Geisser was used as a significance level due to Mauchly’s 
Test of Sphericity not being valid.  Table 6 records the findings.  Again, there was as a 
significant decrease in distress over time, regardless of level of treatment group F (1, 90) 
= 14.99, p < .001.  Additionally, those with worse health status showed a significant 
change over time F (1, 90) = 7.48, p = .008.  However, no interaction between treatment 
condition and time was indicated by these results (see Table 6 and Figure 4).  
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Table 6 
Effect of Treatment Condition Over Time on OQ Scores While Controlling for FACT-G 
Physical Well-Being (PWB) 
Source df Type IV SS MS F 
Within Subjects 
Time 1 2059.79 2059.79 14.99*** 
Time x FACT-G PWB  1 1027.47 1027.47 7.48* 
Time x Tx Condition 1 37.96 37.96 .60 
Error 91 12508.77 137.46  
       Between Subjects 
FACT-G PWB 1 127747.19 127747.19 201.68*** 
Tx Condition 1 1163.08 1163.08 1.84 
Error 91 57640.53 633.41  
 
Note. *p < .05, ** p < .01, ***p < .001.  
 
 
 
 
 
 
Figure 4. Effect of time on treatment level for Total Mean OQ scores while 
controlling for Fact-G physical well-being (x̅ = 19.12).   
 
 
0 10 
20 30 
40 50 
60 70 
80 
Time 1  Time 2 Total OQ Score 
Experimental Group  Control Group 
 62 
Post-Hoc Analyses 
Although it was not demonstrated that treatment condition impacted outcome, it 
was believed this may have been due to an additional variable, engagement.  Participant 
engagement in the treatment varied greatly due to self-selection.  Specifically, 
engagement in the experimental group was measured in the following ways: time in 
seconds on support group website, number of discussion board posts, number of emails 
sent, number of blogs posted, number of live support group chats attended, time in 
seconds in live support group chat, and total chat word count (please see Table 7).  
Because these variables were highly positively skewed (range= 2.82 to 5.53) with a 
great degree of kurtosis (range= 7.70 to 42.00), the variables were computed for the log 
of their original score and transformed.  This procedure created more normally 
distributed variables that were used in all later analyses (skew range = -.63 to .72; 
kurtosis range= -1.48 to -.31). 
 
 
Table 7 
Characteristics of Participant Engagement (Log) 
Engagement  (N = 182) x̅ M % > 0 
    
Time on Website (Seconds) 11722.60  1752.50 100% 
Discussion Board Posts 1.82 0 29.1% 
Emails sent 2.53 0 33% 
Blogs Posted 1.42 0 22.4% 
Live Support Group Chats Attended 0.82 0 20.3% 
Time in Live Support Group Chat (Seconds) 11024.82 0 29.1% 
Total Chat Word Count 466.68 0 25.3% 
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To determine which engagement variables specifically correlated the greatest 
with improvement in OQ distress scores (from baseline to post-treatment), a correlation 
was conducted (See Table 8).   Based on these findings, it appears that change in OQ 
score, or positive improvement in distress, is most positively associated with the total 
time spent engaging with the intervention (r = .313, p < .01).   
 
Table 8 
Correlations Between Change in OQ Score and (Log of) Engagement (N = 182) 
 
Variable 1 2 3 4 5 6 7 8 
1. OQ 
Change 1 
       
2. Total 
Time  .313** 1 
      
3. DB 
Posts .057 .688*** 1 
     
4. Emails 
.039 .737*** .627**
* 
1 
    
5. Blogs 
Posted -.014 .452** .407* 
.397* 
1 
   
6. # 
Chats 
Attended 
.153 .724*** .502** .458** .184 1 
  
7. Chat 
Time -.031 .668*** .350* .397** .237 .625*** 1 
 
8. # Chat 
Words -.185 .667*** .343* .501** .305 .644*** .876*** 1 
 
Note. *p < .01; ** p < .001; *** p < .0001.  
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Thus, another repeated measures ANCOVA was conducted.  The repeated 
measures ANCOVA examined the participant scores from baseline to post-treatment 
with perceived physical well-being, as measured by the FACT-G physical well-being 
subscale, and engagement, as measured by total time spent utilizing the intervention, 
used as covariates.  Because Mauchly’s test of sphericity was invalid, Greenhouse-
Geisser significance levels were noted in Table 9 below.  This time it was shown that 
those who engaged more with the OSG improved over time F (1, 59) = 6.00, p = 0.018. 
 
Table 9 
Effect of Time on OQ Scores While Controlling for FACT-G Physical Well-Being (PWB) 
and Engagement 
Source df Type IV SS MS F 
Within Subjects 
Time 1 35.44 35.44 .386 
Time x FACT-G PWB  1 128.471 128.471 1.40 
Time x Engagement 1 550.97 550.97 6.00* 
Error 60 5508.10 91.80  
       Between Subjects 
FACT-G PWB 1 20628.53 20628.53 29.88*** 
Engagement 1 4120.29 4120.29 5.97* 
Error 60 41422.06 690.37  
 
Note. *p < .05, ** p < .01, ***p < .001.  
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OQ Interpretability 
Based on the previously discussed standards the OQ was interpreted in four 
major categories.  The greatest number of patients were categorized as no change 
(56.5%), followed by recovered (21%), improved (14.5%), and deteriorated (8.1%).  Of 
those in the treatment group, the majority were categorized as no change (56.5%, n=6), 
followed by recovered (23.9%, n=11), improved (8.9%, n=8), and lastly deteriorated 
(2.2%, n=1).  Of those in the control group, the majority were also considered to be in 
the no change category (56.3%, n=9), followed by deteriorated (25%, n=4), then 
recovered (12.5%, n=2), and finally improved (6.3%, n=1).   
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CHAPTER FOUR 
DISCUSSION 
 
This study examined the suitability of the use of the OQ as a PRO in a 
heterogeneous cancer population. As noted previously, Luckett and colleagues (2010) 
suggested the following categories for the evaluation of instrument quality: examination 
of the content, psychometric properties, track record, interpretability, and practical 
issues.  These issues will be elucidated and summarized.  Overall, the results show 
mixed support for the implementation of the OQ as a PRO in a chronic disease sample.  
Generally, if the OQ is to be used as is within a cancer population, the Total Score may 
be interpreted as both reliable and valid and able to demonstrate treatment effects in a 
cancer population, but the subscale scores should not be interpreted.      
 
OQ Content and Psychometric Properties 
 
Content 
The OQ item content was considered suitable (face valid) for a heterogeneous 
cancer population. More so than other PROs, this scale’s content can determine both 
psychological distress and global functioning.  Thus, this measure has a high level of 
face validity for its items. 
 
Reliability 
Consistent with the previous research in general psychiatric populations and the 
 67 
present study’s hypotheses, the OQ Total Score and Symptom Distress subscale 
demonstrated excellent reliability and the Interpersonal Relationships revealed 
good/acceptable reliability.  However, in this study’s sample, the Social Role’s 
reliability was rated as poor although it had measured more highly as 
acceptable/questionable in prior findings.  Consistently between present and previous 
findings the Social Role scale is the least reliable of the three subscales.   
Present results may indicate that either there is a problem with the items that 
construct the Social Role scale or that these results indicate that the social role questions 
were likely not answered as reliably by cancer patients.  It is noted by the researcher that 
some patients verbally commented or transcribed on their PRO that they were confused 
at how to best answer questions regarding their functioning at work or school (despite 
the instructions clarifying this issue) because they were unemployed or taking a leave of 
absence due to health status but also had co-occurring mental health issues.  However, 
perhaps a more clearly defined set of items would clarify this issue and increase the 
reliability of these items.       
 
Validity 
 
Concurrent Validity  
 Concurrent validity findings were mixed for the OQ within this mixed cancer 
population.  As hypothesized, convergent validity was demonstrated across the OQ 
Total Score and subscales.  Although the OQ Total Score did indeed correlate with its 
criterion measures (DT and Fact-G), it was associated the most strongly with the CES-
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D.  Upon examination, the OQ Total score is highly correlated with the Symptom 
Distress subscale.  The Symptom Distress scale, as predicted, was associated most 
strongly with the CES-D as well as the Brief POMS.  Likewise, the Interpersonal 
Relationships subscale also correlated the most strongly with its predicted measures, the 
Fact-G and the SSS.  Unlike the other subscales, the Social Role subscale did not 
correlate strongly with its predicted criterion measures.  While it was significantly 
associated with the Fact-G and SCS, it correlated the most strongly with the Brief 
POMS.   
There are several potential explanations for why the OQ Total Score and Social 
Role subscale may not have correlated strongly with their criterion measures.  The OQ 
Total score may attempt to measure general distress and well-being using three 
subscales, but the total score is so highly associated with the Symptom Distress subscale 
in this population that it is driven by scores on this subscale which highly correlate with 
the CES-D.  Additionally, the Social Role subscale was more strongly associated with 
mood states (Brief POMS) instead of physiological difficulties in completing tasks, 
which the Social Role subscale items also measure.  
Despite hypothesized divergent validity, the OQ Total Score and subscales were 
significantly correlated with each measure selected.   This is likely due to the 
researcher’s poor selection of divergent measures due to underestimation of how highly 
correlated the domains of symptom distress, interpersonal relationships, and social roles 
can be.  Support for this rationale is indicated by the significant correlations between the 
DT, FACT-G, CES-D, Brief Poms, SSS, SCS, and IES-R with all measures as well.   
The researcher selected divergent criterion measures based on the assumption that the 
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subscales of the OQ would represent separate factors and thus not be highly correlated.  
These findings suggest that the current factor structure of the OQ, which is widely used 
in general outpatient psychotherapy settings, may not generalize well to use in cancer 
survivors.    
 
Construct Validity   
As hypothesized, the current factor structure of the OQ was not supported by this 
study, and a differing three-factor model was identified via exploratory factor analysis.  
However, a larger sample size is needed to confirm the new factors identified in this 
study.  This new three-factor model has the following labels: Sense of Well-Being, 
Symptom Distress, and Externalizing Behaviors.  The 15-item Sense of Well-Being 
factor included items that were generally positively worded, i.e. “I am satisfied with my 
life, ” and included items mainly from the prior Symptom Distress and Interpersonal 
Relationships subscales (13 of 15-items).  The 22-item Symptom Distress subscale 
included items that generally reflected symptoms or negative life events such as “I feel 
blue” and generally reflected the previous Symptom Distress subscale items (19 of 22 
items).  The eight-item externalizing behaviors subscale included substance abuse items 
and anger and is mainly composed of the previous scale’s Social Role items (six of eight 
items).  These newly created factors demonstrated at minimum acceptable reliability and 
were forcibly uncorrelated due to the Varimax rotation.   
 Prior literature reflects the likelihood that a new factor structure would be 
necessary, for the pervious articles cited that the current three-factor model was poorly-
fitting and requested exploratory factor analysis to be conducted to further elucidate the 
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domains and subscales exemplified in the OQ.   It is likely that the highly correlated 
nature of the OQ’s subscale domains lead to trouble with these original three factors.  
This makes subscale interpretation of scores difficult.  If the OQ is to be used in a cancer 
population, only the Total Score should be interpreted as valid.  Further research should 
attempt to confirm the factor structure identified here in other populations, both cancer 
and psychiatric, before being generalized.    
 
OQ Track Record 
 As hypothesized, the current study indicated that the OQ was able to demonstrate 
preliminary treatment effects in a RCT of cancer patients engaging in an OSG.  Many 
previous studies that demonstrated the OQ’s track record implemented a more complex 
OQ-feedback system that incorporated the use of the previously mentioned algorithm 
that assesses progress and change and flags cases that may not be on track for 
improvement (e.g., Hawkins, Lambert, Vermeersch, Slade, & Tuttle, 2004; Lambert, 
Whipple, et al., 2001; Lambert, et al., 2002 ; Whipple, et al., 2003).  In these studies, 
part of the intervention included receiving feedback from the OQ itself.  However, the 
current study did not focus on a complex flagging system for the OQ-feedback.  In this 
study, the total OQ scores were viewable by the OSG clinicians, although no effort was 
made to emphasize or track whether clinicians noted this score.  The primary 
intervention was via the online support group. 
When all results were taken into account, the OQ was able to demonstrate an 
improvement in distress over time for those individuals with a worse perception of their 
physical well-being as well as for those who spent more time utilizing the online 
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intervention.  Interestingly, perception of physical well-being was not related to the 
amount of time spent engaging in the intervention (r=-0.015, p= 8.47.) 
 
OQ Interpretability 
 It is also easy to interpret results based on the reliable change index of four.  In 
this study it was found that the majority of individuals (56.5%) made no reliable change 
in their status.  However, 35.5% made a reliable change to recovery or improved by a 
clinically significant amount.  Importantly, a few participants deteriorated (8.1%).   
These numbers are comparable to those found in a meta-analysis of previous OQ studies 
(M. J. Lambert, et al., 2003).  When a multitude of feedback OQ studies were analyzed 
for treatment effects, it was noted that 54.8% made no reliable change, 38.7% made 
reliable change of recovery or improvement, and 6.5% of the sample deteriorated.   
 
OQ Practical Issues 
 This study had less administrator and patient burden than previous studies.  The 
OQ was easily distributed via an email link.  Internet-based point and click answers 
were possible on the Likert-type scale.  The scale was computer-scored and accessible 
via a database as well as linked to support group participants’ profiles.  These profiles 
were viewable by clinicians treating those in the OSG. 
 
Study Limitations and Strengths 
There were many strengths associated with this study as well as some challenges 
and areas that could be improved upon.  First, this study represented the first attempt to 
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examine the reliability and validity of this outcome measure within a cancer population. 
Second, this study used a randomized controlled longitudinal design to assess outcomes 
in an online support group.  However the OQ is a face-valid self-report form, which is 
susceptible to all the inherent flaws within this reporting procedure—accuracy, response 
bias, etc.   
Because participants were required to use the internet for treatment, it is likely 
that this study captured data from those who may otherwise not have been able to 
participate (the extremely ill or those with difficult work schedules) but may also have 
excluded some who would otherwise have participated (those without internet access or 
computer literacy).  Also, many potential participants were eliminated due to an English-
literacy requirement.  Additionally, there may have been a response bias for those who 
chose to respond to the questionnaire when compared with non-responders. 
However, because the trial occurred over the internet we were able to capture 
behavioral data that may be missed in face-to-face groups, i.e. number of conversations 
had with other participants, time spent reading homework, number of words said in 
support group, etc.  However, the drawback to an online group format was potentially a 
lower dose of intervention because individuals could self-select their levels of 
engagement within the treatment group.  Thus, the dose of intervention was self-
determined regardless of treatment status.  Whereas some participant’s engaged 
frequently and often, other participants struggled with attrition and completion of 
follow-up questionnaires.  This problem significantly and dramatically decreased the 
sample size and resulting power for our analyses that included post-test measures and 
was a significant challenge throughout the course of the study.  
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Future Directions 
 Ultimately, there are several areas for future directions of this study.  First, the 
reliability and validity of the OQ should be examined in other cancer populations in 
order to demonstrate support for the findings noted here.  Specifically, a confirmatory 
factor analysis should be utilized within a cancer population to give further evidence to 
the three different factors that were identified in this study.  Next, other face-to-face or 
online studies should examine whether the OQ can demonstrate significance for 
outcomes in other cancer support groups.   
 Another area of interest from this study may be that of the format of the online 
support group itself.  Further studies should examine ways to improve engagement and 
decrease attrition within online support groups.  Some questions that may be asked: what 
is an essential dose of treatment within an online study for participants to clinically 
benefit from it?  What types of interventions are the most effective online?  What do 
people want out of an online support group?  What keeps them returning?  These are 
questions that the future of psychology may quickly need to answer.      
 Particularly, one way to increase engagement may be feedback of the OQ itself 
to online participants.  This study did not utilize feedback of the OQ as part of the 
intervention.  Future studies may attempt to improve treatment effects as well as 
engagement by implementing some of the strategies utilized in prior OQ research.  This 
may include flagging participants who are at risk for not being on track, providing OQ 
scores to participants, and helping both clinician and participant visibly see a graph over 
time of OQ-change with qualitative understanding of the meaning of the change.  
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Summary 
This study identified the suitability of the use of the OQ Total Score as a PRO in 
a heterogeneous cancer population based on the examination of the content, 
psychometric properties, track record, interpretability, and practical issues.  Despite 
some study limitations, this was the first study of its kind to examine the use of this 
measure in a chronic disease population.  Future studies may shed some more light on 
not only the reliability and validity of this measure, but also ways to improve 
engagement and treatment outcomes for cancer populations.   
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